Document:

EXCLUSIVE CO-PROMOTION AGREEMENT

 Exhibit 10.1 
 CONFIDENTIAL 
  
 EXCLUSIVE CO-PROMOTION AGREEMENT 
  
 THIS AGREEMENT is entered into as of October 30, 2003 (the “Effective Date”) by and between CONCEPTUS, INC. a Delaware corporation, having an
address of 1021 Howard Avenue, San Carlos, California 94070 and its permitted assigns hereunder (hereinafter referred to as “CONCEPTUS”), and GYNECARE WORLDWIDE DIVISION
OF ETHICON, INC., a New Jersey corporation, having an address of U.S. Route #22, Somerville, New Jersey 08876 and its permitted assigns hereunder (hereinafter referred to as “GYNECARE”,
together with CONCEPTUS, the “Parties” and each a “Party”). 
  
 RECITALS 
  
 WHEREAS, CONCEPTUS is presently manufacturing and marketing the CONCEPTUS EssureTM permanent birth control device (together with any Improvements thereto and next generation birth control devices, “Essure”);
and 
  
 WHEREAS, GYNECARE is
presently manufacturing and marketing the GYNECARE Thermachoice® uterine balloon therapy system (together with any Improvements thereto and next generation uterine balloon therapy systems, “Thermachoice” and together with
Essure, the “Product Lines” and each a “Product Line”); and 
  
 WHEREAS, each of the Parties has a professional Sales Force (as hereinafter defined) that calls on customers in the Territory (as hereinafter defined) in order to promote their
respective Product Lines; and 
  
 WHEREAS, CONCEPTUS desires to enhance its marketing of Essure in the Territory by enlisting the support and participation of the GYNECARE Sales Force as provided in this Agreement; and 
  
 WHEREAS, GYNECARE desires to enhance its
marketing of Thermachoice in the Territory by enlisting the support and participation of the CONCEPTUS Sales Force as provided in this Agreement. 
  
 AGREEMENT 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  
 1. DEFINITIONS 
  
 An “Affiliate” of a person or entity means any individual, sole proprietorship, firm, partnership, corporation, trust, joint venture or
other entity, whether de jure or de facto, which, directly or indirectly, controls, is controlled by or is under common control with such person or entity. As used in this definition, “control” means the possession, directly
or indirectly, of the power to direct or cause the direction of the policies and management of a person or entity, whether by the ownership of stock, by contract or otherwise. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 “Agreement” shall mean this Exclusive Co-Promotion Agreement. 
  
 “Calendar Quarter” shall mean each of the three (3) month
periods commencing with January 1st, April 1st, July 1st and October 1st and ending, respectively, on the following March 31st, June 30th, September 30th and December 31st. 
  
 “Commercial Year” shall mean each twelve (12) month period starting on the Effective Date or an anniversary
thereof, as applicable, during the Term of this Agreement. 
  
 “CONCEPTUS Patents” shall mean any patent or patent application in the Territory owned or controlled by CONCEPTUS during the Term of this Agreement relating to the Essure, method of manufacture or the use thereof.

  
 “CONCEPTUS Trademarks” shall mean the
trademarks set forth in Schedule A, such marks being owned and registered by CONCEPTUS or a CONCEPTUS Affiliate. 
  
 “Confidential Information” shall have the meaning provided in Section 12.1 hereof. 
  
 “Detail” (or “Details” and
“Detailing”) means, with respect to either or both of the Product Lines, the activity undertaken by a sales representative during a face-to-face sales call on physicians or other health care professionals to provide information on
the use, safety, effectiveness, warnings and other relevant characteristics of either or both of the Product Lines, in a fair and balanced manner consistent with the requirements of the FD&C Act, including, but not limited to, the regulations of
21 CFR Part 202, and using, as necessary or desirable, labeling or promotional materials, in an effort to increase use of the Product Lines. 
  
 “Effective Date” shall be the date shown at the top of page 1 of this Agreement. 
  
 “Essure Labeling” shall mean the labeling described in the
FDA PMA submission for Essure, including but not limited to any required patient information, all labels and other written, printed or graphic matter upon any container, wrapper or any package insert or outsert utilized with or for the Essure
created and developed by or for CONCEPTUS. 
  
 “FDA” shall mean the United States Department of Health and Human Services, Food and Drug Administration or any successor entity. 
  
 “FD&C Act” shall mean the United States Federal Food, Drug and Cosmetics Act, as amended from time to time. 
  
 “GYNECARE Patents” shall mean any patent or patent
application in the Territory owned or controlled by GYNECARE during the Term of this Agreement relating to the Thermachoice device, method of manufacture or the use thereof. 
  
 “GYNECARE Trademarks” shall mean the trademarks set forth in Schedule B, such marks being owned and
registered by GYNECARE or a GYNECARE Affiliate. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 “GYNECARE Managed Strategic Customers” shall mean the list of customers attached hereto
as Schedule C. Such list may be modified by the mutual written agreement of the Parties. 
  
 “Improvements” shall mean any adaptation, change, redesign, improvement, modification or development to a Product Line, the Raw Materials or the method or process of manufacture or process of
manufacture or production of a Product Line. 
  
 “JMC” shall mean the Joint Management Committee formed by the parties to monitor all aspects of the Agreement, discuss issues and advise each Party prior to making certain decisions, including, developing marketing
strategies, plans and budgets for co-marketing the Product Lines and coordinating marketing and sales activities and press releases relating to this Agreement, as further described in Section 2.2 hereof. 
  
 “Marketing Plan” shall have the meaning provided in Section
2.2 hereof. 
  
 “Net Sales” shall mean the
revenue received by a Party, its Affiliates or sublicensees from the sale of its Product Line in the Territory to an independent third party less the following amounts: (i) discounts, including promotional, trade, volume or cash discounts, or
rebates or coupon redemptions actually allowed or granted; (ii) credits or allowances actually granted upon claims or returns or pricing allowances, regardless of the party requesting the return; (iii) freight charges paid for customer delivery;
(iv) sales, use, ad valorem or other taxes or other governmental charges levied on or measured by the invoiced amount whether absorbed by the billing or billed party and (v) allowances or credits to customers for damaged or defective goods.

  
 “Promotion Expenses” shall mean those costs,
excluding corporate and administrative overhead, marketing personnel resources, sales representative costs and incentives but including costs incurred by a Party or for its account which are specifically identifiable to the advertising, promotion
and marketing of the Product Lines by the Parties in the Territory and related professional promotion and education (to the extent not performed by sales representatives), including, without limitation, television and electronic advertisements,
advertorials and infomercials, print advertisements, direct mail, exhibitions at seminars and conferences, promotional samples, sales and promotional literature or other materials and market research, in each case consistent with the Marketing Plan
and otherwise with the terms of this Agreement. 
  
 “Promotional Materials” shall mean all sales representative training materials and all written, printed, graphic, electronic, audio or video matter, including but not limited to journal advertisements, sales visual aids,
leave items, reprints, direct mail, direct-to-consumer advertising, internet postings, broadcast advertisements, and sales reminder aids (for example, scratch pads, pens and other such items), in each case created by the Party or the Parties or on
its or their behalf and used or intended for use by either or both of the Parties in connection with any promotion of either or both of the Product Lines hereunder. 
  
 “Raw Materials” shall mean the materials, components, and packaging required to manufacture and package a
Product Line in accordance with the Specifications. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 “Recommend” or “Recommendation” shall mean in the case of CONCEPTUS,
CONCEPTUS’s sales representatives providing marketing materials and recommending to potential customers the Thermachoice device exclusively over any other endometrial ablation products or procedures for use with the Essure Product Line and in
the case of GYNECARE, GYNECARE’s sales representatives providing marketing materials and recommending to potential customers the Essure device exclusively over any other permanent birth control products or procedures for use with the
Thermachoice. 
  
 “Regulatory Approvals” shall
mean any approvals (including, but not limited to, FDA approval, labeling, pricing and reimbursement approvals), product, biologic and/or establishment licenses, registrations or authorizations of any federal, state or local regulatory agency,
department, bureau or other governmental entity, necessary for the commercial manufacture, use, storage, importation, export, transport or sale of a Product Line in the Territory. 
  
 “Sales Force” of a Party shall mean such Party’s sales personnel calling on customers or potential
customers of a Product Line or the Product Lines in the Territory. 
  
 “Specifications” shall mean the requirements with which a Product Line must conform as specified by 21 CFR §820.181 and device specifications, production process specifications, quality assurance procedures and
specifications, packaging and labeling specifications, and installation, maintenance and servicing procedures and methods that are contained in the Device Master Record for the Product Line. 
  
 “Term of this Agreement” shall have the meaning provided in
Section 8.1 hereof. 
  
 “Territory” shall mean
the United States and its territories and possessions, including overseas United States military establishments. 
  
 “Thermachoice Labeling” shall mean the labeling described in the FDA PMA submission for Thermachoice, including but not limited to any
required patient information, and all labels and other written, printed or graphic matter upon any container, wrapper or any package insert or outsert utilized with or for Thermachoice created and developed by GYNECARE. 
  
 “Third Party” shall mean any entity other than CONCEPTUS or
GYNECARE. 
  
 2. MANAGEMENT 
  
 2.1 Management. The Parties shall establish a Joint Management
Committee consisting of two (2) representatives of each Party which will meet at least twice a year, at mutually agreeable times and locations, to discuss and coordinate the Recommendation and/or Detailing of the Product Lines by the Parties’
Sales Forces in the Territory and the strategies and programs that should be developed to maximize sales of the respective Product Lines. An alternate member designated by a Party may serve temporarily in the absence of a permanent member designated
by such Party. No business shall be transacted at any meeting of the JMC unless a quorum of members is present at the time when the meeting proceeds to business. A quorum shall be at least two (2) members present in person or by their alternate, one
(1) of whom 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 must be a representative appointed by CONCEPTUS and one (1) of whom must be a representative appointed by GYNECARE.
[*] The JMC shall coordinate any announcement, news release, public statement, publication or presentation relating to this Agreement subject to Section 14.15. Each Party shall bear its own costs of participating in the JMC. If the JMC is
unable to reach agreement on an issue, the respective Chief Executive Officers or Presidents of the Parties shall use commercially reasonable efforts to jointly resolve the deadlock 
  
 2.2 Marketing Plan. The JMC shall develop and approve a rolling two-year plan and periodic budgets for each Party for
Recommendation of the Product Lines in the Territory, promotion and Detailing of the Essure Product Line in the Territory, and physician training for Essure, all as provided in this Agreement (the “Marketing Plan”). The Marketing
Plan shall include a marketing, promotion and sales strategy for the co-marketing of the Product Lines by the Parties in the Territory, provided however, each Party shall have the ultimate decision making authority and have complete
discretion over the deployment, marketing, promotion and sales strategy employed by its own Sales Force in connection with the Marketing Plan. The Marketing Plan shall include a budget for each Party for marketing, promotion, clinical and regulatory
expenses relating to the Product Lines during the Term of this Agreement. Each Party agrees to provide for in its own internal, periodic budget, funds to meet its obligations under the mutually agreed upon JMC budget and to expend such funds as
provided in the JMC budget, provided however, neither party shall be required to provide for or expend more than [*] a year pursuant to the JMC budget, unless otherwise agreed to by the Parties. [*] 
  
 2.3 Meetings of the JMC. 
  
 (a) The JMC shall hold meetings at such times and places as shall be
determined by the entire membership of the JMC (it being expected that meetings will alternate between the San Carlos, California offices of CONCEPTUS and the Somerville, New Jersey offices of GYNECARE), but in no event shall such meetings be held
less frequently than twice a calendar year; 
  
 (b) The JMC
may conduct meetings in person or by telephone or video conference or other means, provided that any decision made during a telephone conference meeting is evidenced in writing signed by one (1) of the members of the JMC from each Party; 

 
 (c) By mutual consent of the representatives of each Party, such
consent not to be unreasonably withheld, either Party may invite other personnel of its organization to attend appropriate meetings of the JMC; 
  
 (d) The JMC shall keep minutes reflecting actions taken at meetings; 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (e) The JMC may act without a meeting if prior to such action the JMC members agree regarding such
action and a written consent thereto is signed by the Co-Chairs of the JMC; and 
  
 (f) The JMC may amend or expand upon the foregoing procedures for its internal operations by unanimous written consent. 
  

2.4 Limitations of JMC Powers. The JMC shall not have any power to amend this Agreement or bind or incur liability on behalf of either Party
hereto without such Party’s express prior written authorization, and shall have only such powers as are specifically delegated to them hereunder. 
  
 2.5 Authority to Call Meetings. Notwithstanding the regular meeting schedule of the JMC, a meeting of the JMC may be called by either Party on ten
(10) days written notice to the other, unless such notice is waived by the other Party. In the event of any meeting called pursuant to a notice under this Section 2.5, the Party calling the meeting shall provide with the notice an agenda for the
meeting together with the information that such Party believes is relevant for the items to be discussed. Neither Party shall call more than two (2) additional meetings per Commercial Year for the JMC under this Section 2.5 without the other
Party’s consent. The meeting called under this Section 2.5 shall be held in Chicago, Illinois unless otherwise agreed to by the Parties. 
  
 3. SCOPE; FDA SUPPLEMENT APPROVAL AND CO-PROMOTION OF PRODUCT
LINES 
  
 It is the objective of the Parties
to (a) Recommend and/or Detail as provided below each other’s Product Line to potential customers in the Territory after FDA approval of Supplement 1 and prior to the expiration or termination of this Agreement, and (b) provide for the training
of preceptors and physicians in the Essure and Thermachoice Product Lines. To achieve this and other objectives, the Parties agree as follows: 
  
 3.1 Grant and [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 3.2 FDA Supplement Approval. The Parties shall cooperate in the activities and be
responsible for the expenses necessary to obtain FDA approval for the use of Thermachoice with Essure by supplementing the Essure Pre-Market Approval Application (“PMA”) as set forth on Schedule 3.2. The FDA approval shall be sought in two
(2) separate PMA Supplements, with Supplement 1 seeking approval for the claim that Thermachoice can be safely and effectively used with Essure, but noting the absence of clinical data on expulsion and placement rates (“Supplement 1”) and
with Supplement 2 seeking approval for removing the note regarding expulsion and placement rates from the claim of safe and effective use based on additional clinical studies (“Supplement 2”). To the extent expenses are shared, the Parties
shall jointly own, with full rights of use, the clinical and bench testing data relating to the activities necessary to obtain FDA approval for the use of Thermachoice with Essure and Supplement 1 and Supplement 2. CONCEPTUS shall prepare the
submissions to the FDA and GYNECARE shall 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 have the right to review and comment on the submission, but CONCEPTUS shall conduct all dialogue and contact with the FDA
in connection with the supplemental PMA submissions. The JMC shall first attempt to resolve any disputes between the Parties resulting from any submissions or cost over-runs or delays 
  
 3.3 Preceptors and Physician Training. 
  
 (a) [*] CONCEPTUS shall be responsible for contracting with and training the CONCEPTUS Preceptors. CONCEPTUS, at its
sole expense, shall be responsible for paying all the costs of the training of the Preceptors, including providing the personnel, equipment and samples to teach and certify the CONCEPTUS Preceptors to teach and certify other physicians in the proper
use of the Essure device. CONCEPTUS, upon not less than thirty (30) days written notice, will notify GYNECARE of the times, dates and locations on the training sessions at which the CONCEPTUS Preceptors will be trained. CONCEPTUS will use all
reasonable commercial efforts to contract for and appropriately train the CONCEPTUS Preceptors. 
  
 (b) [*] CONCEPTUS will contract for as independent contractors and be responsible for the payment of the costs of the CONCEPTUS Preceptors, which
payment shall not exceed [*] per full day and [*] per half day of physician training and certification. [*] CONCEPTUS will provide Essure demo devices as needed for each physician to be trained by the CONCEPTUS Preceptors.
[*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 CONCEPTUS shall have the right to review and monitor the physician training conducted by the CONCEPTUS Preceptors and to
recommend any modifications to training to promote consistency and quality or lower cost. 
  
 3.4 Promotion Efforts. After Supplement 1 has been approved by the FDA and prior to the expiration or termination of this Agreement and subject to the terms and conditions of this Agreement, GYNECARE shall
deploy its Sales Force to Recommend and Detail the Essure Product Line and CONCEPTUS shall deploy its Sales Force to Recommend the Thermachoice Product Line in accordance with the Marketing Plan. Each of the Parties acknowledges that the other
Party’s commitments regarding JMC funds under Section 2.2 and training under Section 3.3, and the payments made to it under this Agreement under Article 4 constitute complete and adequate consideration for its entering into this Agreement and
shall constitute complete satisfaction of any duty, whether express or implied, which could be imposed upon the other Party to commercially exploit its rights under this Agreement or to Recommend or Detail the other Party’s Product Line and are
accepted by each Party in lieu of any other minimum promotional efforts obligation on the part of the other Party, including without limitation, with respect to the promotion of the other Party’s Product Line. Each Party acknowledges,
understands and agrees, that it shall not challenge in any subsequent claim or action any decision or action regarding the commercial exploitation of the Products made or taken by any director, officer, employee or individual acting as agent of the
other Party or its Affiliates in what such individual subjectively believes to be in its (or its Affiliate’s) best interests, and that they are not required to take into account the interests of the other Party, unless such decision or action
constitutes a material breach by it of any of its obligations under this Agreement. Except as otherwise expressly agreed to in the Marketing Plan, all business decisions, including, without limitation, the sale, price and promotion of a Party’s
Product Line under this Agreement, shall be within the sole discretion of such Party. 
  
 3.5 Mutual Obligations. 
  
 (a) Each of the Parties shall supervise, train and maintain such competent and qualified sales representatives as may be required to perform the obligations as provided in this Agreement and in the Marketing Plan. GYNECARE shall make
available for CONCEPTUS to train each of GYNECARE’s sales representatives who calls on potential customers in the Territory so that they are qualified to Detail Essure to physicians and CONCEPTUS shall have the right to administer a reasonable
proficiency examination to each such GYNECARE sales representative. CONCEPTUS shall provide sufficient CONCEPTUS personnel, equipment, samples and training for the GYNECARE sales representatives calling on the potential customers in the Territory to
be appropriately trained. This training is expected to be one (1) to two (2) days in total for all GYNECARE sales representatives. [*] GYNECARE will use its commercially reasonable efforts to arrange for its sales representatives to be
trained by CONCEPTUS at mutually convenient times, locations and numbers (but not less than [*] sales representatives per session, unless approved by CONCEPTUS). Each Party shall be responsible for the costs and expenses of its respective
employees, including travel and accommodations, in performing or attending such training. Each Party shall be responsible for the compliance of its Sales Force with all relevant terms of this Agreement and the Marketing Plan. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (b) Each of the Parties shall in all material respects conform its practices and procedures
relating to its obligations under this Agreement for the Recommendation, and/or Detailing and promotion of the Product Lines in the Territory to all applicable laws, regulations and guidelines, including the FD&C Act, the Federal Health Care
Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the Health Industry Manufacturers Association (“HIMA”) and the American Medical Association (“AMA”) Guidelines on Gifts to Physicians from Industry (the
“AMA Guidelines”), as the same may be amended from time to time, and shall promptly notify the other Party of and provide the other Party with a copy of any correspondence or other reports with respect to the Recommendation
Detailing or promotion of the Product Lines submitted to or received from the U.S. Department of Health and Human Services or its components (including the FDA and the Office of the Inspector General), Health Canada, HIMA or the AMA relating to such
laws, regulations and guidelines. 
  
 (c) At one
Party’s reasonable request, the other Party shall provide copies of any written communications disseminated by it generally to its Sales Force promoting the Product Lines in the Territory relating to the Marketing Plan and the joint marketing
strategy for the Product Lines other than compensation, salary or benefit plans or information. 
  
 (d) In connection with the Recommendation, Detailing or promotion of the Product Lines hereunder, no Party shall make any statement, representation
or warranty, oral or written, concerning the Product Lines that is inconsistent with, or contrary to, the Thermachoice Labeling, the Essure Labeling, the Promotional Materials or the Marketing Plan. 
  
 (e) Each of the Parties shall give prompt written notice to the other
Party of the date on which its Sales Force commences promoting the other Party’s Product Line in the Territory. 
  
 (f) Each of the Parties shall use commercially reasonable efforts to promptly refer but shall in no way be responsible for soliciting orders for
the other Party’s Product Lines to the other Party. 
  
 (g) During the term hereof and for a period of six (6) months after the expiration or termination of this Agreement, neither Party shall solicit for employment or employ any officer or employee of the other Party of whom it first
became aware as a direct result of this Agreement; provided that this provision shall not prevent either Party from employing any such persons who contact it on their own initiative (without any actions by such Party to encourage such contact) or
respond to general solicitations of employment not specifically directed towards employees of the other Party. 
  
 3.6 Proprietary Rights in the Product Lines and Promotional Materials. (a) CONCEPTUS retains and shall retain all proprietary rights and
proprietary interests in Essure until the point of sale and in all Promotional Materials relating thereto. GYNECARE will neither have nor represent that it has any control or proprietary or property interests in Essure Promotional Materials solely
developed or created by or on behalf of CONCEPTUS. Nothing 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 contained herein shall be deemed to grant GYNECARE, either expressly or by implication, a license or other right or
interest in any patent, trademark, copyright or other similar property of CONCEPTUS except as may be necessary for GYNECARE to Recommend and Detail Essure as expressly provided for in this Agreement and the Marketing Plan. 
  
 (b) GYNECARE retains and shall retain all proprietary rights and
proprietary interests in Thermachoice until the point of sale and in all Promotional Materials relating thereto. CONCEPTUS will neither have nor represent that it has any control or proprietary or property interests in Thermachoice Promotional
Materials solely developed or created by or on behalf of GYNECARE. Nothing contained herein shall be deemed to grant CONCEPTUS, either expressly or by implication, a license or other right or interest in any patent, trademark, copyright or other
similar property of GYNECARE except as may be necessary for CONCEPTUS to Recommend Thermachoice as expressly provided for in this Agreement and the Marketing Plan. 
  
 3.7 Promotional Materials. 
  

(a) During the Term of this Agreement, CONCEPTUS shall create or co-create and develop with GYNECARE such Promotional Materials solely relating
to Essure as are determined by the JMC to be necessary or appropriate under the Marketing Plan for distribution in the Territory, it being understood that the costs thereof shall be included in Promotion Expenses hereunder. CONCEPTUS shall provide
GYNECARE with such Promotional Materials, in amounts which the Parties jointly determine are reasonable under the terms of the Marketing Plan. CONCEPTUS shall be responsible for complying with all regulatory requirements in the creation of such
Promotional Materials and complying with any applicable government filing requirements. 
  
 (b) During the Term of this Agreement, GYNECARE shall create or co-create and develop with CONCEPTUS such Promotional Materials solely relating to Thermachoice as are determined by the JMC to be necessary or
appropriate under the Marketing Plan for distribution of the Product Lines in the Territory, it being understood that the costs thereof shall be included in Promotion Expenses hereunder. GYNECARE shall provide CONCEPTUS with such Promotional
Materials, in amounts which the Parties jointly determine are reasonable under the terms of the Marketing Plan. GYNECARE shall be responsible for complying with all regulatory requirements in the creation of such promotional materials and complying
with any applicable government filing requirements. 
  
 (c)
Other than with the advice and prior written consent of CONCEPTUS, GYNECARE shall not create or develop sales, promotional or other similar materials relating to the Essure for distribution to Third Parties. 
  
 (d) Other than with the advice and prior written consent of GYNECARE,
CONCEPTUS shall not create or develop sales, promotional or other similar materials relating to Thermachoice for distribution to Third Parties. 
  
 (e) All co-promotional materials, sales materials or other similar materials and materials using a Party’s trademarks, trade names and/or
trade dress shall be reviewed by such Party’s Copy Review/Sign-Off Committee prior to release for use by the other Party. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (f) Notwithstanding anything to the contrary herein, neither Party shall be required to distribute
any Promotional Materials prepared after the Effective Date which it believes in good faith are inaccurate or misleading. The Parties shall distribute Promotional Materials of the type identified in this Section 3.7 in accordance with the terms of
this Agreement and the Marketing Plan. Except as specifically permitted by this Section 3.7, neither Party shall distribute or have distributed any materials bearing the name of the other without the prior written approval of the other. 

 
 (g) CONCEPTUS shall own all right, title and interest in and to the
Promotional Materials relating solely to Essure, including all copyrights appurtenant thereto but excluding any rights in or to the GYNECARE trademark. CONCEPTUS hereby grants to GYNECARE the limited, revocable right, during the Term of this
Agreement, to use Promotional Materials generated pursuant to the Marketing Plan solely in connection with its promotion of Essure hereunder in accordance with the terms of this Agreement and the Marketing Plan. 
  
 (h) GYNECARE shall own all right, title and interest in and to the
Promotional Materials relating solely to Thermachoice, including all copyrights appurtenant thereto but excluding any rights in or to the CONCEPTUS trademark. GYNECARE hereby grants to CONCEPTUS the limited, revocable right, during the Term of this
Agreement, to use Promotional Materials generated pursuant to the Marketing Plan solely in connection with its promotion of Thermachoice hereunder in accordance with the terms of this Agreement and the Marketing Plan. 
  
 (i) The Parties shall jointly own all right, title and interest in and
to the Promotional Materials relating to both Product Lines, including all copyrights appurtenant thereto but excluding any rights in or to the other Party’s trademarks, trade names and/or trade dress. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 3.8 Sales and Distribution; Recalls. Each Party shall have the sole right and responsibility, and
shall bear all costs related thereto, to take such actions with respect to its Product Line in its sole discretion in accordance with legal requirements to maintain the authorization and/or ability to market its Product in the Territory and to
establish the terms and conditions for sale of its Product Line, including, without limitation, the following: manufacturing and distributing, sales, providing customer support in a timely, comprehensive manner, including handling medical queries,
all interactions that are technical or clinical in nature and which require more than a basic knowledge of its Product Line and its characteristics and performing other functions consistent with consumer practice and the Marketing Plan with respect
to its Product Line, responding to product and medical complaints relating to its Product Line, quality assurance, technical support, returns, voluntary and regulatory recalls of product, Regulatory Approvals and compliance, and communications with
regulatory agencies. Notwithstanding the foregoing, each Party may communicate directly with regulatory agencies regarding its own marketing activities. Each Party shall use its commercially reasonable efforts to assist and cooperate with the other
Party as may be necessary or required in any recall or market withdrawal of the other Party’s Product Line and any and all reasonable and documented costs and expenses incurred by the assisting Party shall be reimbursed by the other Party,
except to the extent such recall or market withdrawal was the result of the failure of assisting Party to comply with its obligations under this Agreement. 
  
 3.9 Regulatory Submissions. Each Party, either directly or through a designated Third Party, shall prepare and maintain at its own expense all
technical files and submissions necessary to obtain and maintain all necessary approvals or concurrences required to sell its Product Line in the Territory. 
  
 3.10 Customer Complaints. In accordance with the system of the FDA and all other applicable laws, rules and regulations, each Party shall maintain
responsibility for (i) managing all customer complaints or product inquires relating to its Product Line, (ii) reporting to government agencies and (iii) all corrective action where appropriate. Each Party agrees to provide all necessary and
required support to fulfill all domestic laws and regulations with regards to customer complaints, and vigilance reporting relating to its Product Line. 
  
 4. PAYMENT TERMS. 
  
 4.1 GYNECARE Payments to CONCEPTUS. In consideration for CONCEPTUS granting GYNECARE the exclusive right to Recommend and Detail Essure in the
Territory, GYNECARE shall pay CONCEPTUS [*] within thirty (30) days of the execution of this Agreement and [*] within thirty (30) days of receipt of the FDA approval of Supplement 1. 
  
 4.2 CONCEPTUS Payments to GYNECARE. CONCEPTUS shall pay to GYNECARE
[*] of Net Sales of Essure sold to the GYNECARE Managed Strategic Customers in the Territory during the previous Calendar Quarter commencing with Net Sales occurring on or after the date of the FDA approval of Supplement 1 and continuing
through the Term of the this Agreement (as amended from time to time by the 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 mutual written agreement of the Parties). Within sixty (60) days after the end of each full or partial Calendar Quarter
during the Term of this Agreement, CONCEPTUS shall deliver to GYNECARE a true and accurate report of Net Sales sold by it, its Affiliates and distributors to the GYNECARE Managed Strategic Customers during such Calendar Quarter in the Territory,
accompanied by all payments due under this Section 4.2 for the period covered by such report. Such report shall also include the information reasonably necessary for the GYNECARE to calculate Net Sales to the GYNECARE Managed Strategic Customers of
the Essure product. 
  
 4.3 Method of Payment. Any payments
due to a Party under this Agreement shall be made in U.S. dollars by wire transfer to a bank and account designated in writing by such Party. 
  
 5. TRADEMARKS 
  
 5.1 Essure Labeling; Ownership of CONCEPTUS Trademarks. No CONCEPTUS products distributed by CONCEPTUS in the Territory will bear the GYNECARE
Trademarks without the prior written approval of GYNECARE. The Essure Product Line shall be distributed under the CONCEPTUS Trademarks and ownership and use of the CONCEPTUS Trademarks shall be governed by the following provisions: 
  
 (a) CONCEPTUS or an Affiliate of CONCEPTUS shall retain the ownership
of the entire right, title and interest in and to the CONCEPTUS Trademarks. 
  
 (b) CONCEPTUS shall, at its cost and expense, maintain the CONCEPTUS Trademarks in the Territory. GYNECARE agrees that in using CONCEPTUS Trademarks in its activities under this Agreement it will not represent
in any way that it has any right or title to the ownership of the CONCEPTUS Trademarks or the registration thereof, and the registration will remain in the ownership of CONCEPTUS. Such CONCEPTUS Trademarks will be used by GYNECARE on behalf of, and
in the interest of CONCEPTUS, and GYNECARE will first obtain the written approval of CONCEPTUS of the form and manner in which the CONCEPTUS Trademarks will be used upon, in connection with, or in relation to materials other than Promotion Materials
as may be permitted by this Agreement. 
  
 (c) GYNECARE
recognizes CONCEPTUS’s title in and to the CONCEPTUS Trademarks and to the registration thereof, and will not, at any time, do or authorize any act or thing that will in any way violate or impair the rights of CONCEPTUS in and to the CONCEPTUS
Trademarks and the registration thereof. Wherever CONCEPTUS’s trademarks or tradenames are used, e.g., on any package, label or advertisement, the first or most prominent use shall always be accompanied by a legend acceptable to
CONCEPTUS indicating that EssureTM is a trademark
of CONCEPTUS and the CONCEPTUS trademarks and tradenames are licensed to GYNECARE by CONCEPTUS. 
  
 (d) GYNECARE shall, upon CONCEPTUS’s request, and at CONCEPTUS’s expense, reasonably assist CONCEPTUS in any action reasonably necessary
or desirable to protect the CONCEPTUS Trademarks used or proposed to be used hereunder. GYNECARE shall as soon as practicable notify CONCEPTUS of any apparent infringement by a Third Party of any of the CONCEPTUS Trademarks. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (e) If CONCEPTUS reasonably determines it is necessary to discontinue the use of a CONCEPTUS
Trademark, GYNECARE, after discussion and upon notice and demand from CONCEPTUS, shall immediately discontinue the use of any of the CONCEPTUS Trademarks. In the event of such discontinuance, CONCEPTUS shall select a new CONCEPTUS Trademark to be
used with the Essure and shall promptly notify GYNECARE in writing of such selection. 
  
 5.2 Thermachoice Labeling; Ownership of GYNECARE Trademarks No GYNECARE products distributed by GYNECARE in the Territory will bear the CONCEPTUS Trademarks without the prior written approval of CONCEPTUS. The
Thermachoice Product Line shall be distributed under the GYNECARE Trademarks and ownership and use of the GYNECARE Trademarks shall be governed by the following provisions: 
  
 (a) GYNECARE or an Affiliate of GYNECARE shall retain the ownership of the entire right, title and interest in and to
the GYNECARE Trademarks. 
  
 (b) GYNECARE shall, at its
cost and expense, maintain the GYNECARE Trademarks in the Territory. CONCEPTUS agrees that in using GYNECARE Trademarks in its activities under this Agreement it will not represent in any way that it has any right or title to the ownership of the
GYNECARE Trademarks or the registration thereof, and the registration will remain in the ownership of GYNECARE. Such GYNECARE Trademarks will be used by CONCEPTUS on behalf of and in the interest of, GYNECARE, and CONCEPTUS will first obtain the
written approval of GYNECARE of the form and manner in which the GYNECARE Trademarks will be used upon, in connection with, or in relation to materials other than Promotion Materials as may be permitted by this Agreement. 
  
 (c) CONCEPTUS recognizes GYNECARE’s title in and to the GYNECARE
Trademarks and to the registration thereof, and will not, at any time, do or authorize any act or thing that will in any way violate or impair the rights of GYNECARE in and to the GYNECARE Trademarks and the registration thereof. Wherever
GYNECARE’s trademarks or tradenames are used, e.g., on any package, label or advertisement, the first or most prominent use shall always be accompanied by a legend acceptable to GYNECARE indicating that GYNECARE Thermachoice® is a
registered trademark of GYNECARE and the GYNECARE trademarks and tradenames are licensed to CONCEPTUS by GYNECARE. 
  
 (d) CONCEPTUS shall, upon GYNECARE’s request, and at GYNECARE’s expense, reasonably assist GYNECARE in any action reasonably necessary or
desirable to protect the GYNECARE Trademarks used or proposed to be used hereunder. CONCEPTUS shall as soon as practicable notify GYNECARE of any apparent infringement by a Third Party of any of the GYNECARE Trademarks. 
  
 (e) If GYNECARE reasonably determines it is necessary to discontinue
the use of a GYNECARE Trademark, CONCEPTUS, after discussion and upon notice and demand from GYNECARE, shall immediately discontinue the use of any of the GYNECARE Trademarks. In event of such discontinuance, GYNECARE shall select a new GYNECARE
Trademark to be used with Thermachoice and shall promptly notify CONCEPTUS in writing of such selection. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 6. OPERATING PROCEDURES 
  
 6.1 Exchange of Information. 
  
 (a) Each Party shall provide the other Party with such information
relating to its own Product Line and training as the other Party may reasonably require and request during the Term of this Agreement in order to support the other Party’s effort for the Product Lines as provided in the Marketing Plan.

  
 (b) During the Term of this Agreement and subject to
any other provision of this Agreement, each Party will provide the other Party with all information relevant to the other Party’s performance obligation for their respective Product Lines under this Agreement and the Marketing Plan within the
Territory within a reasonable time after such information becomes known to the Party, provided such information is not received from an independent Third Party under a secrecy obligation. Specifically, the Sales Force of each Party shall receive the
such information at substantially the same time with respect to the Product Lines. 
  
 (c) Each Party shall promptly report to the other Party all information necessary to permit such other Party to make timely reports as required by any governmental regulatory agency in the Territory regarding
the Product Lines and shall promptly report within twenty-four (24) hours any customer complaints or findings associated (i) with the joint use of the Product Lines or (ii) with the use of the Product Lines that may suggest hazards,
contraindications, side effects or precautions pertinent to the safety and/or performance of either of the Product Lines or require the alteration of Recommendation or Detailing activities by a Party’s Sales Force. Each Party agrees to promptly
notify the other Party of any FDA audit, or any audit by any other regulatory body, of its facilities used for the manufacture of its Product Line, or any request for information from the FDA, or other regulatory body, related to the manufacture of
its Product Lines, as soon as practicable after the Party receives notice of such audit or request. All such communications shall be held in confidence by the Parties pursuant and subject to the terms of Article 12. Should either Party learn of any
hazard that is severe, serious or unexpected, concerning the Product Lines, such hazard data shall be communicated to the other Party immediately in writing or confirmed in writing if such immediate communication is non-written. Notwithstanding
anything in this Agreement to the contrary, each Party shall be responsible for complying with all applicable laws regarding the reporting of such hazards to governmental authorities with respect to its own Product Line. The aforementioned
information shall be addressed as follows: 
  
 in the case of

  
 GYNECARE
to:    [*] 
  
 in the case of

  
 CONCEPTUS to:    [*] 
  
 or to such other address as may thereafter be provided by either Party. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (d) Each Party shall respond to medical questions or inquiries relating to their respective
Product Line received by the other Party or at its sole discretion, provide to the other Party, if requested, information to enable the other Party to respond to medical questions or inquiries relating to its Product Line. All such information shall
be held in confidence by the receiving Party pursuant and subject to the terms of Article 12 hereof. Each Party shall use commercially reasonable efforts to keep such information current. The Parties shall coordinate responses to anticipated
inquiries and questions. 
  
 (e) CONCEPTUS shall set up
appropriate sales tracking systems to separately track sales at each GYNECARE Managed Strategic Customer account in the Territory where Essure is purchased and maintain appropriate records thereof. 
  
 6.2 Product Changes. Each Party shall notify the other Party as
soon as possible, but in any event prior to the changed Product Line being sold, of any change in the form, fit or function, or any component or material which would affect the form, fit or function of its respective Product Line, which the other
Party needs to know to perform its obligations under this Agreement or the Marketing Plan lawfully, properly and accurately. 
  
 6.3 Product Recalls. If either Party believes that a recall or market withdrawal of either of the Product Lines is necessary, such Party shall
notify the other Party immediately upon its determination and both Parties shall cooperate to allow such recall or market withdrawal to occur under the direction of the Party whose Product Line is to be recalled (as set forth in Section 3.8). The
Party whose Product Line is to be recalled shall have the final authority with respect to such matters, which authority shall be exercised reasonably and in good faith. 
  
 6.4 Regulatory Obligations. Each Party shall be solely responsible for all activities in connection with the
Regulatory Approvals for their respective Product Line in the Territory, including without limitation communicating and preparing and filing all reports (including without limitation medical device reports) with the FDA. Each Party agrees to
cooperate with the other Party as requested, at the requesting Party’s expense, in preparing and filing all such reports. Each Party shall pay all fees associated with obtaining and maintaining the Regulatory Approvals relating to its Product
Line including, without limitation, any establishment license fees of such Party or Third Parties which must be paid with respect to facilities used in the manufacture of such Product Line. 
  
 6.5 Provision of Information. Each Party shall provide access to
information and data that would support or undermine making the regulatory claim of the concomitant use or use in a preceding or follow-up procedure and/or marketing of the Product Lines at no cost to the other Party upon such Party’s
reasonable request. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 7. ACCOUNTING PROCEDURE 
  
 CONCEPTUS shall keep complete and accurate records in connection with the
payments provided for under this Agreement and the information described in Article 4 hereof. CONCEPTUS shall submit to GYNECARE unaudited quarterly sales records and reports relating to Essure sales during the Term to the GYNECARE Managed Strategic
Accounts (broken down by account) promptly, but in no case, more than sixty (60) days after such Calendar Quarter. GYNECARE shall have the right to nominate an independent firm of certified public or chartered accountants who shall have access no
more than once each year during the Term and once after Termination of this Agreement to the books and records of CONCEPTUS relating to the Essure sales during the Term to the GYNECARE Managed Strategic Accounts during reasonable business hours for
the purpose of verifying any amounts payable, or information provided relating to amounts payable, under this Agreement. The fees and expenses of the accountants performing such verification shall be borne by GYNECARE, unless, in the case of
payments, CONCEPTUS’s records are inadequate to perform such verification or any amount actually due exceeds five percent (5%) or more of amounts reported in which case CONCEPTUS shall bear the costs and expenses of such verification.

  
 8. TERM OF AGREEMENT
AND TERMINATION 
  
 8.1
Term. The term of this agreement (“Term of this Agreement”) shall commence on the Effective Date and continue until the second (2nd) anniversary of the date the FDA approves Supplement 1 or until this Agreement is otherwise terminated or renewed in accordance with its terms. 
  
 8.2 Reversion of Rights Upon Termination or Expiration. Upon any
termination or expiry of this Agreement pursuant to this Article 8, for whatever reason, then, in any such case, all of GYNECARE’s rights hereunder regarding the Essure and the use of the CONCEPTUS Trademarks and the Promotional Materials in
the Territory shall automatically terminate and automatically revert to CONCEPTUS, effective as of such time, and GYNECARE shall have no further rights thereto (except as set forth in Section 8.3 below) and all of CONCEPTUS’s rights hereunder
regarding Thermachoice and the use of the GYNECARE Trademarks and the Promotional Materials in the Territory shall automatically terminate and automatically revert to GYNECARE, effective as of such time, and CONCEPTUS shall have no further rights
thereto (except as set forth in Section 8.3 below). 
  
 8.3
Effect of Termination. Termination of this Agreement in whole or in part shall not relieve CONCEPTUS of any amounts owed to GYNECARE, nor shall it relieve the Parties of their obligations with respect to the Product Lines distributed in the
Territory during the Term of this Agreement, or with respect to limiting disclosure and use of Confidential Information. Notwithstanding anything to the contrary herein, if GYNECARE terminates this Agreement pursuant to Section 8.5, 8.6(iii) or
8.6(iv), the provisions of Section 4.2 shall survive for two (2) years after the termination of this Agreement. Upon termination or expiration hereof, GYNECARE shall promptly return to CONCEPTUS all Promotional Materials and samples of 

 

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 Essure then in the possession of GYNECARE, its Affiliates and any of their respective Sales Forces and CONCEPTUS shall
promptly return to GYNECARE all Promotional Materials and samples of Thermachoice then in the possession of CONCEPTUS, its Affiliates and any of their respective Sales Forces. 
  
 8.4 Termination. (a) CONCEPTUS shall have the right to terminate this Agreement if GYNECARE fails to have available
for training the [*] CONCEPTUS Preceptors within the time provided in Schedule 3.2, unless such failure is caused by CONCEPTUS, or fails to identify and make available for training at least [*] physicians of the total number of
physicians to be certified for use in the Essure Product Line in any twelve (12) month period as required in Paragraph 3.3. GYNECARE shall have no other liability to CONCEPTUS for such failure. 
  
 (b) GYNECARE shall have the right to terminate the Agreement immediately upon
notice to CONCEPTUS if a court rejects the [*] and CONCEPTUS or if the settlement agreement between [*]. and CONCEPTUS expires or is terminated for any reason. In the event of a termination by GYNECARE under this Section 8.4(b),
CONCEPTUS shall reimburse GYNECARE for any and all of the expenses it has undertaken pursuant to this Agreement, including but not limited to, the payments made by GYNECARE under Section 4.1 hereof, the training of physicians, preceptors and sales
representatives in Essure and its efforts and expenses associated with seeking and obtaining Supplement 1 and Supplement 2. 
  
 (c) GYNECARE shall have the right to terminate the Agreement upon written notice if CONCEPTUS fails to obtain FDA approval for Supplement 1 on or prior to
[*]. 
  
 (d) GYNECARE shall have the right to terminate the
Agreement upon written notice if GYNECARE or CONCEPTUS is unsuccessful in gaining procedure adoption from the trained and certified physicians due to negative clinical experience or if the concomitant procedure is unfavorably reimbursed.
Unsuccessful procedure adoption shall be defined as an average of one (1) or fewer procedures involving the concomitant use of Thermachoice and Essure performed per month per physicians trained and certified in Essure under this Agreement for any
four (4) month period during the term of this Agreement. Unfavorable reimbursement shall be defined as device reimbursement for the concomitant use which is less that the average selling price of each of the two (2) Product Lines when used
separately. 
  
 8.5 Termination for Insolvency. Either
Party shall have the right to terminate this Agreement immediately effective upon written notice to the other Party in the event the non-notifying Party becomes insolvent or makes an assignment for the benefit of creditors, or in the event
bankruptcy or insolvency proceedings are instituted against the non-notifying Party or on the non-notifying Party’s behalf. 
  
 8.6 Other Termination. Each Party shall have the right to terminate this Agreement immediately effective upon written notice to the other Party in
the event that (i) the manufacture, use or sale of the other Party’s Product Line has been determined by a court of competent jurisdiction to infringe the proprietary intellectual property rights of a Third Party or (ii) its activities
hereunder are determined by an appropriate regulatory agency or court to be in 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 violation of any applicable law, rule or regulation and such violation cannot be remedied by reasonable modifications of
this Agreement or (iii) the other Party is in material breach of Section 13, or (iv) the other Party is in material breach of any other representation, warranty, covenant, agreement or obligation under this Agreement and fails to cure such breach
within twenty (20) days of a written notice from the non-breaching Party, or if a cure cannot reasonably be effective in such time, fails to commence in such time or fails to diligently pursue a cure to completion or (v) the other Party’s
Product Line has been subject to a recall or market withdrawal. 
  
 8.7 Exercise of Right to Terminate. The use by either Party hereto of a termination right provided for under this Agreement shall not give rise to any liability or the payment of damages or any other form of compensation or relief to
the other Party with respect thereto. 
  
 8.8 Damages;
Relief. Subject to Section 8.7 above and 14.9 below, termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it may be entitled to upon such termination. For the avoidance of
doubt, any claim for damages, compensation or relief under this Section 8.8 shall be brought under Section 14.9. 
  
 8.9 Renewal Term. Subject to the Parties rights to terminate this Agreement as provided herein, the Parties may mutually agree to extend the Term
of this Agreement for one (1) or more successive additional twelve (12) month renewal terms. Nothing in this Agreement shall be deemed to prevent Party from declining to extend the Term or from requiring modification the terms of the Agreement as a
condition to any extension. 
  
 9. REPRESENTATIONS
AND WARRANTIES. 
  
 9.1
Mutual Representations and Warranties. Each of the Parties hereby represents and warrants to the other Party as follows: 
  
 (a) such Party (i) is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated,
(ii) has the corporate power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted, and (iii) is in
compliance with all requirements of applicable law, except to the extent that any noncompliance would not have a material adverse effect on the properties, business, financial or other condition of such Party and would not materially adversely
affect such Party’s ability to perform its obligations under this Agreement; 
  
 (b) this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, and the execution, delivery and performance of the Agreement by such Party does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over
it. Each Party expressly represents and warrants that it has the full power and authority to enter into this Agreement and to carry out the obligations contemplated hereby; 
  
 (c) it has taken all necessary corporate action on its part to authorize the execution and delivery of this
Agreement; 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (d) the manufacture, use, importation, offer for sale or sale of its Product Line as contemplated
hereunder does not infringe any Third Party’s intellectual property right; 
  
 (e) the use of its trademarks, trade names or trade dress pursuant to the terms of this Agreement and the Marketing Plan does not and will not infringe the rights of any third party; 
  
 (f) that with respect to all regulatory filings to obtain Regulatory
Approvals, the data and information in such Party’s submissions are and shall be free from fraud and/or material falsity, that the Regulatory Approvals have not been and will not be obtained either through bribery or the payment of illegal
gratuities, that the data and information in such Party’s submissions are and shall be accurate and reliable for purposes of supporting approval of the submissions, and that the Regulatory Approvals shall be obtained without illegal or
unethical behavior of any kind; 
  
 (g) it has obtained, to
the extent it is required to do so, all necessary governmental approvals required in connection with the manufacture, sale and marketing of its Product Line in the Territory, including but not limited to PMA approval from the FDA; no governmental
authority has threatened any action to revoke any governmental approval for its Product Line, and that the submissions which it made to the FDA were made in good faith and contained accurate and complete data and information regarding its Product
Line as required by applicable laws, rules and regulations; it shall maintain for the term of this Agreement or any extension thereof all PMA approval for its Product Line; furthermore, it shall file, and maintain at its own cost for its Product
Line, all appropriate registrations with the FDA and similar regulatory authorities in the Territory countries which have the authority to approve the sale of its Product Line for use in humans; and 
  
 (h) during the term of this Agreement or any extension thereof, its
Product Line shall be of merchantable quality, fit for the purpose intended by this Agreement and free from defects in design, material and workmanship and manufactured and delivered in accordance with the terms of this Agreement, all applicable
present and future statutes, laws, and regulations, including without limitation, good manufacturing practices (“GMP”), QSRs and ISO 9000 requirements and that during the term of this Agreement or any extension thereof its Product Line
will not be adulterated or misbranded at the time of delivery to Third Parties within the meaning of the FD&C Act. 
  
 9.2 Performance by Affiliates and Third Parties. The Parties recognize that each Party may perform some or all of its obligations under this
Agreement through its Affiliates provided, however, that each Party shall remain responsible for the performance by its Affiliates and shall cause such parties to comply with the provisions of this Agreement in connection with such performance. Each
Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate for any obligation or performance hereunder prior to proceeding directly against such Party. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 10. OWNERSHIP OF INTELLECTUAL PROPERTY AND
PATENT RIGHTS. 
  
 10.1
Intellectual Property. CONCEPTUS shall have sole ownership of all right, title and interest in the Essure, CONCEPTUS Patents, CONCEPTUS Trademarks and Essure Labeling. GYNECARE shall have sole ownership of all right, title and interest in
Thermachoice, GYNECARE Patents, GYNECARE Trademarks and Thermachoice Labeling. 
  
 10.2 Patent Prosecution. CONCEPTUS shall have the sole right, but not the obligation, to file applications for, prosecute and maintain the CONCEPTUS Patents. CONCEPTUS shall not be obligated to disclose to
GYNECARE any prosecution information relating to the CONCEPTUS Patents. GYNECARE shall have the sole right, but not the obligation, to file applications for, prosecute and maintain the GYNECARE Patents. GYNECARE shall not be obligated to disclose to
CONCEPTUS any prosecution information relating to the GYNECARE Patents. 
  
 10.3 Enforcement Rights. 
  
 (a) Notification
of Infringement. (i) If GYNECARE learns of any misappropriation of any CONCEPTUS Patents, CONCEPTUS Trademarks or Information (the “CONCEPTUS Product Rights”), or any infringement or threatened infringement by a Third Party of
the CONCEPTUS Patents in the Territory, GYNECARE shall promptly notify CONCEPTUS and shall provide CONCEPTUS with all available evidence of such misappropriation or infringement. 
  
 (ii) If CONCEPTUS learns of any misappropriation of any GYNECARE Patents, GYNECARE Trademarks or Information (the
“GYNECARE Product Rights”), or any infringement or threatened infringement by a Third Party of the GYNECARE Patents in the Territory, CONCEPTUS shall promptly notify GYNECARE and shall provide GYNECARE with all available evidence of
such misappropriation or infringement. 
  
 (b) Enforcement of
Patents and Product Rights in the Territory. (i) CONCEPTUS shall have the sole right, but not the obligation, to institute, prosecute and control at its own expense any action or proceeding with respect to infringement of any CONCEPTUS Patents
or any misappropriation of the CONCEPTUS Product Rights in the Territory, by counsel of its own choice. GYNECARE shall cooperate with CONCEPTUS, at CONCEPTUS’s expense, in any such action or proceeding brought by CONCEPTUS against a Third
Party. Any amounts recovered by CONCEPTUS pursuant to this subsection (b) shall belong exclusively to CONCEPTUS. 
  
 (ii) GYNECARE shall have the sole right, but not the obligation, to institute, prosecute and control at its own expense any action or proceeding
with respect to infringement of any GYNECARE Patents or any misappropriation of the GYNECARE Product Rights in the Territory, by counsel of its own choice. CONCEPTUS shall cooperate with GYNECARE, at GYNECARE’s expense, in any such action or
proceeding brought by GYNECARE against a Third Party. Any amounts recovered by GYNECARE pursuant to this subsection (b) shall belong exclusively to GYNECARE. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 (c) Settlement with a Third Party. CONCEPTUS shall have the sole right to control settlement of
actions relating to the CONCEPTUS Product Rights and GYNECARE shall have the sole right to control settlement of actions relating to the GYNECARE Product Rights. 
  
 11. INDEMNIFICATION; INSURANCE 
  
 11.1 Indemnification by CONCEPTUS. Except as set forth in Section 11.2 hereof, and except to the extent caused by
GYNECARE’s or its Affiliates’ or agent’s negligent, reckless or willful acts or omissions, CONCEPTUS shall indemnify, defend and hold GYNECARE and its Affiliates and their directors, officers, employees and, agents harmless from and
against any liabilities, damages, costs or expenses, including reasonable attorneys’ fees (collectively, “Liabilities”), (a) which arise out of, relate to or result from the breach by CONCEPTUS of any of its representations,
warranties, covenants or other agreements contained within this Agreement; (b) which arise from any claim, lawsuit, alleged damage, or other action by a Third Party (a “Claim”), which Claim is caused by or is alleged to have been caused by
the design, manufacture, use or sale of Essure during the Term of this Agreement and/or the training provided by CONCEPTUS to the CONCEPTUS Preceptors or the training provided by the CONCEPTUS Preceptors to physicians under Section 3.3 hereof; (c)
which are attributable to statements or representations by CONCEPTUS, its employees, or its agents, that are inconsistent with, or contrary to, the Essure Labeling, the Thermachoice Labeling, or Promotional Materials; (d) which, in the case of any
trademark infringement claim, lawsuit or other action, result solely from GYNECARE’s proper use of CONCEPTUS Trademarks in accordance with the terms of this Agreement; or (e) which arise from a claim, lawsuit or other action by a Third Party
that the manufacture, use of sale of the Essure infringes the patent, copyright or other intellectual property right of a Third Party, except in each case (a) – (e) to the extent such Claim results from GYNECARE’s negligence or willful
misconduct. 
  
 11.2 Indemnification by GYNECARE. Except as
set forth in Section 11.1 hereof, and except to the extent caused by CONCEPTUS’s or its Affiliates’ or agent’s negligent, reckless or willful acts or omissions, GYNECARE shall indemnify, defend and hold CONCEPTUS and its Affiliates
and their directors, officers, employees and, agents harmless from and against any Liabilities, (a) which arise out of, relate to or result from the breach by GYNECARE of any of its representations, warranties, covenants or other agreements
contained within this Agreement; (b) which arise from any Claim, which Claim is caused by or is alleged to have been caused by the design, manufacture, use or sale of Thermachoice during the Term of this Agreement; (c) which are attributable to
statements or representations by GYNECARE, its employees, or its agents, that are inconsistent with, or contrary to, the Thermachoice Labeling, the Essure Labeling, or Promotional Materials; (d) which, in the case of any trademark infringement
claim, lawsuit or other action, result solely from CONCEPTUS’s proper use of GYNECARE Trademarks in accordance with the terms of this Agreement; or (e) which arise from a claim, lawsuit or other action by a Third Party that the manufacture, use
of sale of the Thermachoice infringes the patent, copyright or other intellectual property right of a Third Party, except in each case (a) – (e) to the extent such Claim results from CONCEPTUS’s negligence or willful misconduct.

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 11.3 Indemnification Procedure. In the event that any Party seeks to assert a right to
indemnification pursuant to Sections 11.1 or 11.2, as appropriate, such Party shall promptly provide the other Party with written notice of the claim for indemnity and full information concerning the claim. The indemnified Party shall have the right
select its own counsel and control the defense. The indemnified Party shall be entitled to reimbursement of its costs and expenses, including attorneys’ fees, related to the indemnified matter from the indemnifying Party on a quarterly basis,
which reimbursement shall be due within thirty (30) days after receipt of an itemized invoice from the indemnified Party. No Party shall settle or compromise any claim, action or matter with respect to which indemnification has been sought without
the other Party’s prior written consent, which consent shall not be unreasonably withheld. The indemnified Party shall keep the indemnifying Party informed with respect to actions taken by it with regard to the matter. Failure of any Party to
give prompt notice of a claim for indemnification shall not affect its right to indemnification except to the extent that the indemnifying Party shall have been prejudiced as a result of such failure, and except that the indemnifying Party shall not
be liable for any expenses incurred during the period in which the indemnified Party failed to give notice. 
  
 11.4 Insurance. Each Party, at its own expense, shall maintain comprehensive general/product liability insurance with at least the minimum
coverages set forth on Schedule 11.4. Each Party’s insurance policy shall require at least thirty (30) days’ notice to the other Party prior to cancellation or material change in the policy. Each Party shall provide that its insurance will
include the other Party as an additional insured party. Such notices of cancellation or material change shall be given in accordance with Section 14.7 hereof. 
  

12. CONFIDENTIALITY  
  
 12.1 Confidential Information. The Parties hereto recognize that non-public and/or confidential technical, scientific and other data and
information relating to the Product Lines, as well as information relating to a Party’s technology, know-how, processes, patent applications, trade secrets, inventions ideas, formula or test data relating to any research project, work in
process, future development, engineering, manufacturing, regulatory, marketing, servicing, financing or personnel matters, present or future products, sales, suppliers, clients, customers, employees, investors or business, whether in oral, written,
graphic or electronic form (hereinafter referred to collectively as “Confidential Information”), disclosed by one Party or its Affiliates to the other or its Affiliates hereunder, is of considerable value to the disclosing Party and
is to be considered highly confidential. The Parties agree that the terms and conditions of this Agreement and the Marketing Plan shall be deemed to be the Confidential Information of each Party and disclosure of such will be limited to members of
the JMC and those persons in the respective organizations that have a need to know. The Parties further agree that, subject to the rights in Section 12.4, the GYNECARE Managed Strategic Customers shall be deemed to be the Confidential Information of
GYNECARE only. References to the receiving Party in this Article 12 refer to CONCEPTUS and its Affiliates, if any, on the one hand, and GYNECARE and its Affiliates, on the other hand, as the case may be. 
  
 The Parties will, through the JMC, mutually agree on the Information which is
to presented to the doctors relating to the Detailing of the Product Lines. This Information is not considered to be Confidential Information. Each of the Parties will limit the dissemination of Confidential Information of the other Party throughout
its organization to those with a need to know. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 The amount of Confidential Information to be disclosed shall be completely within the discretion of the
disclosing Party. To the extent practical, Confidential Information shall be disclosed in tangible form and marked as “Confidential.” Information disclosed in an intangible form, such as orally or by visual inspection, shall not be
considered Confidential Information unless the disclosing Party confirms in writing the fact and general nature of the disclosure within one (1) month after it is made. 
  
 Notwithstanding anything in this Agreement to the contrary, neither Party shall at any time provide the other Party with any
technical information or data, including but not limited to, technical information relating to their respective Product Lines, including but not limited to, information and data relating to formulation, analytical methods, unless such technical
information is already in the public domain. 
  
 12.2
Obligation to Maintain Confidentiality of Information. Each Party hereby covenants not to use Confidential Information of the other Party received by it or its Affiliates, or any part thereof, outside the Territory and not to use such
Confidential Information of the other Party, or any part thereof, except as expressly authorized or pursuant to the terms of this Agreement. In addition, each receiving Party shall keep all Confidential Information of the other Party received by it
or its Affiliates in complete confidence and shall not disclose or make such Confidential Information of the other Party, or any part thereof, available to Third Parties except: 
  
 (a) For the purpose of obtaining and maintaining any necessary Regulatory Approvals for the sale of Product Lines
under this Agreement in the Territory; 
  
 (b) To the
extent that the disclosing Party may agree in writing, such agreement shall be obtained prior to such disclosure by receiving Party; 
  
 (c) To the extent that such Confidential Information can be demonstrated by written records or other credible evidence to be known to the receiving
Party or its Affiliates at the time of receipt thereof from the disclosing Party or becomes known to the receiving party other than from the disclosing Party or their authorized employees or agents (provided that such source is not prohibited from
disclosing such portions to the Recipient by any contractual, fiduciary or other legal obligation); and 
  
 (d) To the extent that such Confidential Information is or may become a matter of public knowledge by virtue of the action of a party other than
the receiving Party or its Affiliates. 
  
 12.3 Information
Disclosed Prior to Effective Date. Section 12.2 above shall also apply to the Information disclosed by a Party or its Affiliates to the other Party or its Affiliates prior to the Effective Date of this Agreement. 
  
 12.4 Survival of Obligation. Obligations under this Article 12 shall
be in force during the Term of this Agreement and any extension hereof and shall survive expiration or termination (as the case may be) of this Agreement for a period of five (5) years. Notwithstanding the 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 
foregoing, neither Party shall be prohibited or restricted in any marketing or selling of its Product Lines to any party, including any party that is one of
the GYNECARE Strategic Managed Customers, after the termination of this Agreement, if such marketing and selling is part of an effort targeted at a general market of which some or all of the GYNECARE Managed Strategic Customers are a part, provided
however, if GYNECARE terminates this Agreement pursuant to Section 8.5, 8.6(iii) or 8.6(iv) the provisions of Section 4.2 shall survive for two (2) years after the termination of this Agreement. 
  
 13. COMPLIANCE 
  
 13.1 Compliance with Certain Laws. Each Party agrees to comply with
the applicable provisions of any Federal or state law and all executive orders, rules and regulations issued thereunder, whether now or hereafter in force, including Executive Order 11246, as amended, Chapter 60 of Title 41 of the Code of Federal
Regulations, as amended, prohibiting discrimination against any employee or applicant for employment because of race, color, religion, sex or national origin; Section 60-741.1 of Chapter 60 of 41 Code of Federal Regulations, as amended, prohibiting
discrimination against any employee or applicant for employment because of physical or mental handicap; Section 60.250.4 of Chapter 60 of 41 Code of Federal Regulations, as amended, providing for the employment of disabled veterans and veterans of
the Vietnam era; Chapter 1 of Title 48 of the Code of Federal Regulations, as Amended, Federal Acquisition Regulations; Sections 6, 7 and 12 of the Fair Labor Standards Act, as amended, and the regulations and orders of the United States Department
of Labor promulgated in connection therewith; and any provisions, representations or agreements required thereby to be included in this Agreement are hereby incorporated by reference. If either Product Line is ordered by Distributor under U.S.
government contracts, each Party agrees that all applicable federal statutes and regulations applying to the other Party as a contractor are accepted and binding upon it insofar as it may be deemed a subcontractor. 
  
 13.2 Compliance with Policy on the Employment of Young Persons. Each
Party and its officers have read and understand the Johnson & Johnson Policy on the Employment of Young Persons (the “Policy”) attached as Schedule 13.2 hereto. In the manufacture and supply of its Product Line hereunder, each Party
shall employ young persons only as permitted by the Policy. Each Party shall permit representatives of the other Party to enter its premises at any reasonable time, and each Party shall ensure that representatives of the other Party shall be
permitted to enter the premises of any subcontractor involved in the manufacture or supply of its Product Line (or component thereof) at any reasonable time, in order to inspect relevant employment, health and safety records and to observe the
manufacturing process. Each Party (and its subcontractors) shall maintain the records necessary to demonstrate compliance with the Policy and shall provide to the other Party a written certification of such compliance annually during the term of
this Agreement. If a Party shall fail to comply with this Section, then the other Party shall have the right to terminate this Agreement forthwith, effective upon ten (10) days’ prior written notice, and without payment of any penalty or
termination fee, if the other Party has not cured such breach within such time. 
  
 13.3 Environment, Safety and Industrial Hygiene. Each Party hereby certifies that it is in compliance with all environmental, safety and industrial hygiene matters related to its activities under this
Agreement. With respect to all environmental, safety and industrial hygiene 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 
matters related to a Party’s activities under this Agreement, each Party shall (a) comply with all applicable laws and regulations issued by national,
state and local authorities, (b) inform the other Party promptly of any significant adverse event (e.g., fires, explosions, accidental discharges) and (c) inform the other promptly of any allegations or findings of violations of applicable laws or
regulations. If a Party fails to meet any of these conditions, the other Party may terminate this Agreement upon ten (10) days prior written notice to the other Party if the other Party has not cured such breach within such time. 
  
 14. GENERAL PROVISIONS 
  
 14.1 Integration/Modification. This Agreement by and between the
Parties hereto, is both a final expression of the Parties’ agreement and a complete and exclusive statement with respect to all of its terms. The Schedules and other documents and agreements referred to or contemplated by in this Agreement,
including the Marketing Plan, are incorporated herein and made a part of this Agreement by this reference. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and
all matters contained herein. No rights or licenses with respect to CONCEPTUS Patents, CONCEPTUS Trademarks, Essure Labeling, Promotional Materials relating to Essure, GYNECARE Patents, GYNECARE Trademarks, Thermachoice Labeling, Promotional
Materials relating to Thermachoice are granted or deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement. No trade customs, courses of dealing or courses of performance by the Parties shall be
relevant to modify, supplement or explain any term(s) used in this Agreement. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement. 
  
 14.2 Relationship Between the Parties. The Parties have no ownership
interest in the other and their relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither
Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 
  
 14.3 Non-Waiver. The failure of a Party to insist upon strict
performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any
other instance. 
  
 14.4 Assignment. This Agreement is
binding upon and inures to the benefit of the Parties to it, and to their permitted successors and assigns. No Party may assign or delegate any or all of its rights or obligations under this Agreement without the prior written consent of the Party
to this Agreement, which consent shall not be unreasonably withheld provided the proposed assignee is fully capable of performing the assignor’s obligations under this Agreement. This Agreement may be transferred to any party which acquires all
or substantially all of the ownership or assets of a Party, whether by acquisition or merger, and nothing in this 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 
Agreement shall be deemed to prevent or preclude a Party from entering into and consummating such a sale or merger or from acquiring any other entity;
provided, however, that in such event either Party shall have the right, at its sole discretion, to terminate this Agreement thirty (30) days after providing written notice of termination or upon the closing of the transaction, whichever date is
later. Any assignment or delegation, or any other transfer or change of control by sale, acquisition, merger, or otherwise, or attempt at the same, other than as permitted hereunder, made in the absence of such prior written consent shall be void
and without effect. If a Party assigns this Agreement to an Affiliate, such Party will also promptly inform the other Party and guarantee the performance by its Affiliate of all of such Party’s obligations under the Agreement. 
  
 14.5 No Third Party Beneficiaries. This Agreement is neither expressly
nor impliedly made for the benefit of any party other than those executing it. 
  
 14.6 Severability. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or
in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or
illegal part. 
  
 14.7 Notices. Any notice to be given
under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified
at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; (b) if
mailed, three (3) calendar days after the date of postmark; or (c) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries. 
  
 If to GYNECARE, notices must be addressed to: 
  
 [*] 
  
 With a copy to [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 In the case of notices given pursuant to Section 11.4: 
  
 [*] 
  
 With a copy to: 
  
 [*] 
  
 If to CONCEPTUS, notices must be addressed to: 
  
 [*] 
  
 With a copy to: 
  
 [*] 
  
 In the case of notices given pursuant to Section 11.4: 
  
 [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 14.8 Force Majeure. Except for the obligation to make payment when due, each Party shall be
excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party’s reasonable control including but not limited to Acts of God, fire, flood, explosion, earthquake, or
other natural forces, war, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other event similar to those
enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party’s
failure or delay in performance due to force majeure must be given to the other Party within ten (10) calendar days after its occurrence. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the
duration of such force majeure. In no event shall any Party be required to prevent or settle any labor disturbance or dispute. Notwithstanding the foregoing, should the event(s) of force majeure suffered by a Party extend beyond a three (3) month
period, the other Party may then terminate this Agreement by written notice to the non-performing Party, with the consequences of such termination as set forth in Sections 8.2 and 8.3. 
  
 14.9 Arbitration. Any controversy or claim arising out of or relating to this Agreement or the validity, inducement,
or breach thereof, but excluding Third Party claims (“Disputes”) shall be first mediated by the Parties in an effort to reach a mutual resolution. Such mediation shall be before a mediator jointly agreed upon or, if such agreement cannot
be reached, by a mediator selected from three mediators proposed by the Chicago office of the American Arbitration Association, with each party having the right to reject one of the candidates. Each Party agrees to mediate in good faith for not less
than eight (8) hours. If the Dispute is not resolved by mediation, it shall be settled by arbitration before a single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”)
then pertaining, except where those rules conflict with this provision, in which case this provision controls. If the Parties cannot agree on an arbitrator, the AAA office holding the arbitration shall provide three qualified candidates and each
Party shall have the right to reject one candidate. Any such arbitration decision may be enforced by any court of competent jurisdiction. The arbitrator shall be an attorney who has at least fifteen (15) years of experience with a law firm or
corporate law department of over twenty-five (25) lawyers or was a judge of a court of general jurisdiction. The arbitration shall be held in [*] and in rendering the award the arbitrator must apply the substantive law of [*] (except
where that law conflicts with this clause), except that the interpretation and enforcement of this arbitration provision shall be governed by the Federal Arbitration Act. The arbitrator shall be neutral, independent, disinterested, impartial and
shall abide by The Code of Ethics for Arbitrators in Commercial Disputes approved by the AAA. Within forty-five (45) days of initiation of arbitration, the Parties shall reach agreement upon and thereafter follow procedures assuring that the
arbitration will be concluded and the award rendered within no more than eight (8) months from selection of the arbitrator. Failing such agreement, the AAA will design and the Parties will follow procedures that meet such a time schedule. Each Party
has the right before or, if the arbitrator cannot hear the matter within an acceptable period, during the arbitration to seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc., to
avoid irreparable harm, maintain the status quo or preserve the subject matter of the arbitration. 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 
THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES INCLUDING LOSS OF PROFITS, AND EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES. 
  
 EACH
PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY DISPUTE BY JURY. 
  
 EACH PARTY HERETO WAIVES ANY CLAIM TO PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES INCLUDING LOSS OF PROFITS FROM THE OTHER. 
  
 14.10 Legal Fees. If either Party to this Agreement resorts to any legal action or arbitration in connection with this Agreement, the prevailing
Party shall be entitled to recover reasonable fees of attorneys and other professionals in addition to all court costs and arbitrator’s fees which that Party may incur as a result. 
  
 14.11 Governing Law. Notwithstanding its place of execution or performance, this Agreement shall be governed by and
construed in accordance with the laws of the [*], irrespective of its laws regarding choice or conflict of laws. 
  
 14.12 Interpretation 
  
 (a) Captions & Headings. The captions and headings of clauses contained in this Agreement preceding the text of the articles, sections,
subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. 
  
 (b) Singular & Plural. All references in this Agreement to the
singular shall include the plural where applicable, and all references to gender shall include both genders and the neuter. 
  
 (c) Articles, Sections & Subsections. Unless otherwise specified, references in this Agreement to any article shall include all sections,
subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such sections; and references in this Agreement to any subsection shall include all paragraphs in such
subsection. 
  
 (d) Days. All references to days in this
Agreement shall mean calendar days, unless otherwise specified. 
  
 (e) Ambiguities. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 
  
 14.13 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 14.14 Further Assurances. Each Party to this Agreement shall, at its own expense, furnish,
execute, and deliver all documents and take all actions as may reasonably be required to effect the terms and purposes of this Agreement. 
  
 14.15 Public Disclosure. The Parties hereto covenant and agree that, except as provided for herein below and as expressly specified in the
Marketing Plan, each will not from and after the date hereof make, issue or release any public announcement, press release, statement or acknowledgment of the existence of, or reveal publicly the terms, conditions and status of, the transactions
contemplated herein, without the prior written consent of the other Party as to the content and time of release of and the media in which such statement or announcement is to be made; provided, however, that in the case of
announcements, statements, acknowledgments or revelations which either party is required by law to make, issue or release, the making, issuing or releasing of any such announcement, statement, acknowledgment or revelation by the party so required to
do so by law shall not constitute a breach of this Agreement if such party shall have given not less than five (5) business days prior notice to the other Party if possible, and in any case shall have obtained the other Party’s prior written
approval of such announcement, statement, acknowledgment or revelation. Except as permitted by this Agreement, neither Party shall not use the name of the other Party or any of its Affiliates for advertising or promotional purposes without the prior
written consent of the other Party. In furtherance of the foregoing, neither Party shall originate any publicity or other announcement, written or oral, whether to the public, the press, the trade, either Party’s customers or otherwise,
relating to this Agreement or the existence of an arrangement between the parties, without the prior written approval of the other Party. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 IN WITNESS WHEREOF, the Parties, intending to be
bound hereby, have executed this Agreement as of the date first written above. 
  

									
	CONCEPTUS, INC.	 	 	 	 ETHICON, INC. BY ITS 
 WORLDWIDE DIVISION GYNECARE

					
	 By:
	 	  

	 	 	 	 By:
	 	  

					
	 Name:
	 	 Mark Sieczkarek
	 	 	 	 Name:
	 	  

					
	 Title:
	 	 President & CEO
	 	 	 	 Title:
	 	  

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SCHEDULE A 
  

CONCEPTUS TRADEMARKS 
  
 Essure 
  
 Conceptus 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SCHEDULE B 
  

GYNECARE TRADEMARKS 
  
 GYNECARE 
  
 Thermachoice® 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SCHEDULE 3.2 
  
 PRE-MARKETING APPROVAL AND EXPENSE 
  
 [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SCHEDULE C 
  

GYNECARE MANAGED STRATEGIC CUSTOMERS 
  
 [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SCHEDULE 11.4 
  
 Insurance Coverages 
  
 [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately. 

 SHEDULE 13.2 
  
 JOHNSON & JOHNSON POLICY 
  

ON THE EMPLOYMENT OF YOUNG PERSONS 
  
 [*] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately.SHARE PURCHASE AND CALL OPTION AGREEMENT

 Exhibit 10.2 
  
 SHARE PURCHASE AND CALL OPTION AGREEMENT 
  
 Between 
  
 Mr. Yves Guillemain d’Echon 
 Mr.
Jean-Christophe Bodin 
 Mrs. Catherine Guillemain d’Echon 
 Mr. Florent Guillemain d’Echon 
 Mr. Alban Guillemain d’Echon 
 Mr. Tristan Guillemain d’Echon 
 Mr. Jean
Guillemain d’Echon 
 Mrs. Katia Bodin 
 Miss. Fabienne Gairin 
 Miss. Isabelle Viroulet 
 Miss. Aurélie Blanchard 
 Mr. Didier Pinget 
 Mr. Eric Tourraud 
 Mr. Philippe Maréchal 
  
 (The Purchasers and Grantors) 
  
 and 
  
 Conceptus Inc. 
  
 (The Seller and Beneficiary) 
  

January 17, 2004 

 TABLE OF CONTENTS 
  

					
	1	  	DEFINITIONS	  	4
			
	2	  	SALE AND PURCHASE OF THE SHARES	  	7
			
	3	  	PURCHASE PRICE AND PAYMENT OF THE PURCHASE PRICE	  	7
			
	4	  	ACTIONS TO BE TAKEN ON THE TRANSFER DATE	  	7
			
	5	  	REPRESENTATIONS AND WARRANTIES	  	8
			
	6	  	POST TRANSFER OF THE SHARES - COVENANTS OF THE PARTIES	  	8
			
	7	  	CALL OPTION (PROMESSE DE VENTE)	  	10
			
	8	  	INDEMNIFICATION	  	17
			
	9	  	POST TRANSFER OF THE OPTION SHARES - COVENANTS OF THE PARTIES	  	19
			
	10	  	NOTICES	  	21
			
	11	  	MISCELLANEOUS	  	22

 SHARE PURCHASE AND CALL OPTION AGREEMENT 
  
 This share purchase and call option agreement is entered into on January 17, 2004,

  
 BETWEEN: 
  

	1.	Conceptus Inc., a company organized under the laws of the State of Delaware, the registered office of which is at 1021 Howard Ave, San Carlos, CA, 94019, United States of
America, represented by Mark Siezckarek in his capacity of President and Chief Executive Officer, duly authorized for the purpose hereof, 

  
 (hereinafter referred to as the “Seller” or the “Beneficiary”), 
  
 On the one hand, 
  
 AND: 
  

	2.	Mr. Yves Guillemain d’Echon, born on July 30, 1956, at Nevers, France, French citizen, living at 4, Passage Saladin 78000 Versailles, married under the
communauté réduite aux acquêts regime, 

  

	3.	Mr. Jean-Christophe Bodin, born on February 25, 1957, at Neuilly sur Seine, French citizen, living at 3, rue Charles Gounod 94440 Santeny, married under the séparation des
biens regime,  

  
 (the parties 2 and 3 are
acting jointly and severally and hereinafter referred to as the “Managers”), 
  

	4.	Mrs. Catherine Guillemain d’Echon, née Johanet, born on June 22, 1958, at Donzy, French citizen, living at 4 Passage Saladin 78000 Versailles, married under the
communauté réduite aux acquêts regime, 

  

	5.	Mr. Florent Guillemain d’Echon, born on February 28, 1982, at Oullins, France, French citizen, living at 4, passage Saladin 78000 Versailles, single,

  

	6.	Mr. Alban Guillemain d’Echon, born on August 5, 1983, at Lyon, France, French citizen, living at 4, passage Saladin 78000 Versailles, single,

  

	7.	Mr. Tristan Guillemain d’Echon, born on August 15, 1985, at Cosnes-Cours sur Loire, France, French citizen, living at 4, passage Saladin 78000 Versailles, single,

  

	8.	Mr. Jean Guillemain d’Echon, born on September 10, 1981, at Clermont Ferrand, France, French citizen, living at c/o Mr. Camus, 75, rue Dutot 75015 Paris, single,

  

	9.	Mrs. Katia Bodin, née Agostini, born on August 30, 1966, at Metz, France, French citizen, living at 3, rue Charles Gounod 94440 Santeny, married under the
séparation des biens regime, 

  

 -2- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	10.	Miss. Fabienne Gairin, born on September 20, 1957, at Lorient, France, French citizen, living at 37, avenue Lucien René Duchesne, Bâtiment 8, 78170 La Celle
Saint Cloud, divorced, 

  

	11.	Miss. Isabelle Viroulet, born on July 7, 1973, at Saint Ouen, France, French citizen, living at 3, Cité de l’Alma, 75007 Paris, single,

  

	12.	Miss. Aurélie Blanchard, born on July 4, 1982, at Agen, France, French citizen, living at Résidence la Muette 1 Square Raynouard, 78150 Rocquencourt,
single, 

  

	13.	Mr. Didier Pinget, born on November 28, 1961, at Sainte Foy le Lyon, French citizen, living at 9 Boulevard des Brotteaux 69006 Lyon, married under the séparation des
biens regime, 

  

	14.	Mr. Eric Tourraud, born on June 5, 1954, at Paris, France, French citizen, living at 4, rue de la Pinte 66000 Perpignan, divorced, 

  

	15.	Mr. Philippe Maréchal, born on April 24, 1962, at Juvisy, French citizen, living at 12, avenue de Verdun 78170 La Celle Saint Cloud, married under the séparation
des biens regime,  

  
 (the parties 4 to 15
are acting jointly and severally and are hereinafter referred to as the “Managers Partners”), 
  
 The Managers and Managers Partners acting jointly and severally and are hereinafter referred to collectively as the “Purchasers” or the “Grantors”. 
  
 In the presence of for the purpose of Section 4.2, Section 6 and Section 7.1.2 hereof
only: 
  

	16.	Conceptus SAS, a company organized under the laws of France, the registered office of which is at 7/9 rue du Maréchal Foch, registered at the Versailles register under
the number 440 204 964, represented by Mr. Yves Guillemain d’Echon in his capacity of Président, duly authorized. 

  
 (hereinafter referred to as the “Company”), 
  
 The Seller/Beneficiary and the Purchasers/Grantors are hereinafter referred to individually as a “Party” and collectively as the
“Parties”. 
  
 RECITALS: 
  

	(A)	The Seller, a NASDAQ-listed Delaware company, owns the intellectual property rights related to a pregnancy control device called ESSURE (“Essure”).

  

	(B)	The Seller owns directly 100% of the shares in Conceptus SAS (the “Company”), a French Société par Actions Simplifiée, with a share
capital of € 50,000 divided into 5,000 identical shares (the “Shares”). 

  

	(C)	The Company is engaged in the business of the distribution of medical products. 

  

	(D)	The Purchasers have agreed to acquire the Shares from the Seller and the Seller has agreed to sell the Shares to the Purchasers under the terms and conditions of this Agreement.

  

 -3- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

 NOW, THEREFORE, the Parties agree as follows: 
  

	1	DEFINITIONS 

  
 For the purpose of this Agreement: 
  

			
	Accounting Principles	  	shall mean the accounting principles applied by the Company in accordance with French GAAP.
		
	Agreement	  	shall mean this share purchase and call option agreement including its recitals and the Disclosure Schedule.
		
	Audited Financial Statements	  	shall have the meaning set forth in Article 7.5.5.
		
	Beneficiary	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Business Day	  	shall mean any day other than Saturday, Sunday, a legal holiday or a day on which banking institutions in Paris, France are closed.
		
	Call Option	  	shall have the meaning set forth in Article 7.
		
	Claim	  	shall have the meaning set forth in Article 8.3.
		
	Claim Notice	  	shall have the meaning set forth in Article 8.3.
		
	Closing Actions	  	shall have the meaning set forth in Article 4.2.
		
	Companies	  	shall mean the Company and its Subsidiaries, if any.
		
	Company	  	shall have the meaning set forth in paragraph B of the Recitals.
		
	Confirmation of the Call Option	  	shall have the meaning set forth in Article 7.1.4.
		
	Disclosure Schedule	  	shall have the meaning set forth in Article 7.1.3.
		
	Distribution Agreement	  	shall have the meaning set forth in Article 4.1.
		
	Due Diligence	  	shall have the meaning set forth in Article 7.1.
		
	Due Diligence Disclosure	  	shall have the meaning set forth in Article 7.1.
		
	Due Diligence Documents	  	shall have the meaning set forth in Article 7.1.
		
	Due Diligence Period	  	shall have the meaning set forth in Article 7.1.
		
	Escrow Agent	  	shall have the meaning set forth in Article 7.3.
		
	Essure	  	shall have the meaning set forth in paragraph A of the Recitals.

  

 -4- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

			
	Fiscal Year	  	shall mean the fiscal year of the Company commencing on January 1 and ending on December 31 of each year.
		
	Governmental Authority	  	shall mean the United States, the European Union and any of its member states or any political subdivision thereof, any other nation, state, province, municipality or other jurisdiction of
any nature, any entity or body exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to government and any governmental or judicial tribunal of competent jurisdiction.
		
	Grantors	  	shall mean the individuals listed at the beginning of this Agreement and the individuals who may adhere to this Agreement as Grantors pursuant to section 7.4.1 below.
		
	Indemnified Parties	  	shall have the meaning set forth in Article 8.1.1.
		
	Law	  	shall mean any law, statute, rule, regulation, ordinance, directive, order or decree of any Governmental Authority.
		
	Lien	  	shall mean any security interest, mortgage, lien, pledge, charge, or other form of security interest, encumbrance, “servitude” or restriction on use, voting or transfer or,
generally, any third party right, that has the purpose or the effect of restricting the ownership of any asset or security.
		
	Loss	  	shall have the meaning set forth in Article 8.1.1.
		
	Managers	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Managers Partners	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Material Adversely Affects	  	when used with respect to any event, circumstance, condition, fact, effect, or other matter, shall mean that such event, circumstance, condition, fact, effect, or other matter, has or is
reasonably likely to have a material adverse effect on the business, assets, condition (financial or otherwise), prospects, results or operations of one or all the Companies.
		
	Notice	  	shall have the meaning set forth in Article 10.1.
		
	Notice of Interest	  	shall have the meaning set forth in Article 7.1.
		
	Option Period 0	  	shall have the meaning set forth in Article 7.1.
		
	Option Period 1	  	shall have the meaning set forth in Article 7.1.
		
	Option Period 2	  	shall have the meaning set forth in Article 7.1.
		
	Option Period 3	  	shall have the meaning set forth in Article 7.1.
		
	Option Periods	  	shall have the meaning set forth in Article 7.1.
		
	Option Shares	  	shall have the meaning set forth in Article 7.
		
	Option Purchase Price	  	shall have the meaning set forth in Article 7.2.1.
		
	Ordinary Course of Business	  	shall mean the ordinary course of business consistent with past custom and practice (including with respect to quantity and frequency).

  

 -5- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

			
	Other Products Option	  	shall have the meaning set forth in Article 7.1.
		
	Parties	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Person	  	shall mean any individual or any corporation, association, partnership, joint venture, limited liability, joint stock or other company, business trust, trust, organization, business or
government or any governmental agency or political subdivision thereof.
		
	Profitable	  	shall mean in relation to the Company that the consolidated net profit of the Audited Financial Statements preceding the Notice of Interest is equal to a minimum positive 1 Euro for the
previous Fiscal Year based on the latest Audited Financial Accounts.
		
	Purchase Price	  	shall have the meaning set forth in Article 3.
		
	Purchasers	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Sales Revenue for Conceptus Products	  	shall mean the revenue resulting from the sales of Conceptus Inc. products.
		
	Sales Revenue for Non-Conceptus Products	  	shall mean the revenue resulting from the sales of products which are not Conceptus Inc. products.
		
	Schedule(s)	  	shall mean the schedule(s) attached hereto.
		
	Seller	  	shall have the meaning set forth at the beginning of this Agreement.
		
	Shares	  	shall have the meaning set forth in paragraph B of the Recitals.
		
	Subsidiaries	  	shall mean in relation to any specified Person any company or other entity in which such Person owns directly or indirectly more than fifty percent (50%) of the capital stock or voting
rights.
		
	Tax or Taxes	  	shall mean all direct or indirect taxes, charges, imposts, fees, duties, levies or other assessments or governmental charges of any kind, and any charge in the nature of taxation, whether
payable directly or by withholding (wherever imposed), including, without limitation, all net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, withholding, payroll, employment, social security (including
any health, unemployment, housing, family allowances, pension or retirement contributions or similar payroll-related charges, taxes or assessments), excise, severance, property, local (including taxe professionnelle) or other taxes, duties,
fees, assessments or charges of any kind whatsoever, including any interest thereon, and penalties, fines or additional amounts in relation, or attributable, thereto, and any payment made in or in relation thereto, imposed by any Governmental
Authority.
		
	Tax Return	  	shall mean any return, report, information return, statement, declaration or other document (including any related or supporting information) filed or required to be filed with any
Governmental Authority in connection with any determination, assessment or collection of any Tax or other administration of any Laws, regulations or administrative requirements.

  

 -6- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

			
	Territory	  	shall have the meaning set forth in the Distribution Agreement.
		
	Transfer Date	  	shall mean the date hereof.
		
	Transfer of the Option Shares	  	shall have the meaning set forth in Article 7.3.
		
	Transfer of the Option Shares Date	  	shall mean the date of consummation of the sale of the Option Shares to the Beneficiary by delivery of the documents referred to in Article 7.3 hereof against payment of the Option Purchase
Price.
		
	Transfer of the Shares	  	shall have the meaning set forth in Article 2.1.

  

	2	SALE AND PURCHASE OF THE SHARES 

  

	2.1	The Seller agrees to sell to the Purchasers, and the Purchasers agree to purchase from the Seller all of the Shares, in the proportions set out in Schedule 2.1 hereto, for
the consideration specified in Article 3 and upon completion of the actions to be taken specified in Article 4, on the Transfer Date (said sale and purchase being herein referred to as the “Transfer of the Shares”).

  

	2.2	Upon completion of the Transfer of the Shares, the Purchasers shall have the possession, use and ownership of the Shares and shall be subrogated to all the rights and obligations
attached to the Shares including the right to the full amount of all dividends which might be paid as from the Transfer Date. 

  

	3	PURCHASE PRICE AND PAYMENT OF THE PURCHASE PRICE 

  
 In light of the financial situation of the Company, the total purchase price for the Shares shall be equal to one (1) euro (the “Purchase
Price”) which shall be paid on the Transfer Date. 
  

	4	ACTIONS TO BE TAKEN ON THE TRANSFER DATE 

  

	4.1	On the Transfer Date: 

  
 (i) the Seller shall deliver or cause to be delivered to the Purchasers duly executed share transfer orders (ordres de mouvement) to transfer the
Shares to the Purchasers; 
  
 (ii) Mr. Yves Guillemain
d’Echon shall pay on behalf and for the account of the Purchasers the Purchase Price to the Seller; 
  
 (iii) the Seller and the Company shall enter into, on the Transfer Date, a distribution agreement attached as Schedule 4.1 hereto, (the
“Distribution Agreement”). 
  

 -7- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	4.2	For the avoidance of doubt, it is specified that all of the actions listed in this Article 4.2 and 4.1 (the “Closing Actions”) is conditional upon the occurrence of
all of the others, so that if one of the Closing Actions does not occur, the Party that is not responsible for taking that action to occur shall be entitled to refuse to proceed with the closing and shall incur no liability vis-à-vis the
other Party in connection with such refusal without prejudice to its right to seek and obtain any remedy that may be available under applicable law. 

  

	5	REPRESENTATIONS AND WARRANTIES 

  

	5.1	Representations and warranties of the Seller 

  

	 	5.1.1	Mr. Yves Guillemain d’Echon having managed and operated the Company since December 14, 2001, as C.E.O. (Président), the Purchasers acknowledge that they have full
knowledge of the Company’s activities and operations and confirm that they are capable of evaluating the merits and risks of their purchase of the Shares. 

  
 As a consequence, the Seller does not grant to the Purchasers any representation or warranty whatsoever related to the
Shares or the Company and its activities and operations, other than those granted pursuant to Article 5.1.2. 
  

	 	5.1.2	The Seller represents and warrants that: 

  

	 	(i)	the Shares are validly owned by the Seller; 

  

	 	(ii)	the Shares represent all of the issued share capital of the Company; 

  

	 	(iii)	the Shares are free and clear of any Liens; 

  

	 	(iv)	no increase in share capital nor distribution of dividends has been decided by the shareholders of the Company between June 30, 2003 and the Transfer Date; and

  

	 	(v)	the execution and delivery of the Agreement by the Seller and the consummation by the Seller of the Transfer of the Shares have been duly approved by the relevant corporate body of
the Seller. 

  

	5.2	Representations and Warranties of the Purchasers 

  
 The Purchasers represent and warrant that: 
  

	 	(i)	they have full Knowledge of the Company’s activities, operations and financial situation and that, following the Transfer of the Shares, the Company will no longer benefit from
the financial support of the Seller. 

  

	 	(ii)	they have the necessary financial resources to support the Company so that it can, after the Transfer of the Shares, carry out its activity as it does today.

  

	6	POST TRANSFER OF THE SHARES - COVENANTS OF THE PARTIES 

  

	6.1	Transition 

  
 Following the Transfer of the Shares, the Parties agree to jointly inform the customers with respect to the transfer of control of the Company. The Parties shall mutually agree on the format, content, place and date
of such notices. 
  

 -8- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	6.2	Regulatory Issues 

  
 As from the Transfer Date, the Company shall have full responsibility to obtain any and all regulatory approvals that are or may become necessary to
operate the Company and conduct its business. 
  
 This
responsibility excludes the right to obtain, manage or maintain the CE mark related to the products manufactured or marketed by the Seller. The full responsibility for the CE mark will remain with the Seller, who will agree to keep the mark valid
for the term of this Agreement and the Distribution Agreement. The Seller will assign as necessary any rights to the CE mark necessary for the Company to operate in the Territory defined in the Distribution Agreement. 
  
 To the extent permitted by applicable Law, the Seller undertakes to assign
or otherwise have the Company, at the Company’s costs, benefit from, any and all legal and regulatory approvals which it holds as of the Transfer Date and which are reasonably necessary for the sale, distribution or promotion of Essure within
the Territory authorized under the Distribution Agreement between the Seller and the Company and relating to Essure. 
  

	6.3	Outstanding agreements 

  
 No costs, fees, or other expenses resulting from (i) any agreement entered into between the Seller and a third party (other than the Company) and/or (ii)
employees of the Seller, shall be incurred or borne by the Company. 
  

	6.4	Non Solicitation of Employees 

  
 For three years following the Transfer Date, the Parties undertake and shall cause their representatives and employees to undertake (and, for the
avoidance of doubt, the Purchasers shall cause the Company to undertake), whether on their own account or for the account of any other Person, not to contact, solicit or endeavor to entice away from the other Party or hire any person who was
employed by it on the Transfer Date or at any time within a period of one year prior to that date, without the other Party’s consent. 
  

 -9- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	6.5	Limitation of the Activity of the Company 

  

	 	6.5.1	Notwithstanding the Call Option, the Purchasers shall have a complete independence in managing the Company, it being understood that the activity of the Company shall be limited to
distribution activities and activities ancillary to distribution activities. The Company shall not, and the Purchasers will procure the Company not to enter into distribution, promotional or acquisition agreements for Non-Conceptus Products which
are directly or indirectly of a competitive nature with the Conceptus products. If the Company distributes products which are not produced by the Seller, the Purchasers shall procure that the Company maintains clear and distinct accounting of assets
and resources used for distribution activities or activities ancillary to it for the Non-Conceptus Products, in order to allow accurate valuation of the Company profitability regarding solely the Conceptus Products. The Company will, and the
Purchasers will procure that, the Company ensure that all agreements to distribute non-Conceptus Products will allow the Company to terminate said agreement, at its sole discretion, without incurring any indemnification, costs or penalty whatsoever
with at most a 90-day notice period. 

  

	 	6.5.2	Additional Undertaking of the Purchasers 

  
 It will be the responsibility of the Purchasers to remove any signatories of the Seller from any existing banking accounts, power of attorneys or other
legal or financial instruments of the Company at or after the Transfer Date. 
  

	6.6	Additional Undertaking of the Managers 

  
 In addition to any indemnification, undertaking and guarantee granted hereby by the Managers, the Managers irrevocably jointly and severally guarantee and
undertake to procure (“se portent fort”) the fulfillment of all the obligations of the Managers Partners under this Agreement. 
  

	7	    CALL OPTION (Promesse de Vente) 

  

In accordance with the terms and subject to the conditions of this Agreement, the Grantors hereby grant to the Beneficiary an option to purchase
all (but not some only) of the issued and outstanding shares in the Company existing at the time the Call Option is exercised (the “Option Shares”) for the price determined as specified below, payable to the Grantors by the
Beneficiary for the Option Shares in the event of the exercise of such option (the “Call Option”). 
  
 The Beneficiary accepts the benefit of the Call Option as an option solely without hereby undertaking to exercise it. 
  

	7.1	Exercise of the Call Option 

  

	 	7.1.1	The Call Option shall be exercisable by written notice sent by the Beneficiary to the Grantors’ and Managers’ Agent (the “Notice of Interest”) at any
time: 

  

	 	1.	Between the Transfer Date and the beginning of Option Period 1 (the “Option Period 0”); 

  

	 	2.	During the three-month period starting as from (i) [*] and (ii) no later than [*] (the “Option Period 1”); 

  

 -10- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	 	3.	During the three-month period starting as from (i) [*] and (ii) no later than [*] (the “Option Period 2”); 

  

	 	4.	During the three-month period starting as from (i) [*] and (ii) [*] (the “Option Period 3”) 

  

	 	5.	For each successive year after [*], and as long as the Distribution Agreement is in force between the Company and the Beneficiary, during the three-month period starting as
from (i) [*], and (ii) no later than [*] of each year. The Option Purchase Price for the Call Option Periods after [*] will be the same as Option Period 3 defined in Section 7.2.1. 

  
 The Option Period 0, the Option Period 1, the Option Period 2, the Option
Period 3 and the option periods defined in Article 7.1.1 (5) above are collectively referred to hereby as the “Option Periods”. 
  
 The Call Option may be exercised by the Beneficiary for all (but not some only) of the Option Shares at any time during the Option Periods. 
  

	 	7.1.2	As from the notice of exercise of the Call Option, the Beneficiary shall benefit from a thirty (30) days period (the “Due Diligence Period”) during which it shall
be able to conduct a due diligence of the Company (the “Due Diligence”). The Grantors and the Company will provide the Beneficiary full access to the premises and personnel of the Company as well as to any document and notably all
financial, accounting, legal, tax and corporate documents and including without limitation all the necessary information and documents required to evaluate the Option Purchase Price (including the products sale contracts and the margin per
contracts, turnover for the Sales Revenue for Conceptus Products and Non-Conceptus product, on a monthly basis and the monthly reporting) and all documents and information in response to any due diligence request list sent to Grantors by the
Beneficiary. The Grantors shall cooperate fully with the Beneficiary and its representatives during the Due Diligence Period. 

  
 At the end of the Due Diligence Period, the Beneficiary shall provide the Grantors’ and Managers’ Agent with copies of all the information and
documents provided to the Beneficiary during the Due Diligence Period (the “Due Diligence Documents”). Following the provision of the Due Diligence Documents, the Managers will have five Business Days to complete such Due Diligence
Documents by notifying by written notice to the Beneficiary any additional information or document. The completed Due Diligence Documents, once approved by the Beneficiary and the Managers, shall constitute the “Due Diligence
Disclosure”. 
  

 -11- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	 	7.1.3	Before the end of the Due Diligence Period, the Grantors’ and Managers’ Agent shall provide the Beneficiary with a document setting forth the disclosures required by the
representations and warranties provided for in Article 7.5 of the Agreement (the “Disclosure Schedule”). 

  

	 	7.1.4	Within twenty (20) days of the end of the Due Diligence Period, and provided it has received the Disclosure Schedule and the Due Diligence Disclosure, the Beneficiary will confirm
the exercise of the Call Option by written notice by the Beneficiary to the Grantors’ and Managers’ Agent (the “Confirmation of the Call Option”). Absent any such confirmation, the Beneficiary shall be deemed not to have
exercised the Call Option and will be under no obligation to purchase the Option Shares (unless it exercises the Call Option again in accordance with Article 7.1.1 et seq.) 

  

	 	7.1.5	The Beneficiary, if and when confirming the exercise of the Call Option and if mutually agreeable to the Grantor, shall have the right to review for potential purchase the
distribution rights to Non-Conceptus Products (the “Other Products Option”) in accordance with Article 7.2. However, following the Transfer of the Option Shares, the Company shall not be required to continue to distribute the
Non-Conceptus Products and shall be entitled to terminate these agreements, as set out in Article 6.5.1, in case the Other Products Option is not exercised. 

  

	7.2	Option Purchase Price 

  

	 	7.2.1	Should the Beneficiary exercise the Call Option, the sale of the Option Shares shall be made at a price determined according to this Article 7.2 (the “Option Purchase
Price”): 

  

					
	 	 	 On Option Period 0

	Beneficiary does not exercise the Other Products Option	 	[*]
		
	Beneficiary exercises the Other Products Option	 	[*]
		
	 	 	 On Option Period 1

	 	 	 Should the Company be
 Profitable

	 	Should the Company not be
Profitable

	Beneficiary does not exercise the Other Products Option	 	[*]	 	[*]
			
	Beneficiary exercises the Other Products Option	 	[*]	 	[*]

  

 -12- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

					
	 	  	On Option Period 2

	 	  	Should the Company be
Profitable

	 	Should the Company not be
Profitable

	Beneficiary does not exercise the Other Products Option	  	[*]	 	[*]
			
	Beneficiary exercises the Other Products Option	  	[*]	 	[*]
		
	 	  	 On Option Period 3 and on
 each options periods defined in
 Article 7.1.1 (5)

	 	  	Should the Company be
Profitable

	 	Should the Company not be
Profitable

	Beneficiary does not exercise the Other Products Option	  	[*]	 	[*]
			
	Beneficiary exercises the Other Products Option	  	[*]	 	[*]

  

	 	7.2.2	As an exception to the foregoing, in the event of a change of control of the Beneficiary and irrespective of section 7.2.1 and whether the Company is Profitable or not, the price
would be determined as follows: 

  

			
	 	  	On Option Period 0 and Option Period 1

	Beneficiary does not exercise the Other Products Option	  	[*]
		
	Beneficiary exercises the Other Products Option	  	[*]
		
	 	  	On Option Period 2

	Beneficiary does not exercise the Other Products Option	  	[*]
		
	Beneficiary exercises the Other Products Option	  	[*]

  

 -13- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

			
	 	  	 On Option Period 3 and on
 each options periods defined in
 Article 7.1.1
(5)

	Beneficiary does not exercise the Other Products Option	  	[*]
		
	Beneficiary exercises the Other Products Option	  	[*]

  
 In the event of a change of control of
the Beneficiary and irrespective of section 7.2.1 and whether the Company is Profitable or not, the Option Purchase Price for the Call Option Periods after [*] will be the same as Option Period 3 defined in this Section 7.2.2. 
  

	 	7.2.3	For the avoidance of doubt, for the purposes of calculating the Option Purchase Price, the Parties agree that in order to determine the amount of the Sales Revenue for Conceptus
Products and/or the Sales Revenue for Non-Conceptus Products, only the products sold under normal terms and conditions in accordance with market or past practices will be taken into account. 

  
 If the Grantors and the Beneficiary are unable to agree on the Option
Purchase Price (which includes the Profitability, the Sales Revenue for Conceptus Products and/or the Sales Revenue for Non-Conceptus Products determination), such amount shall be finally determined by PriceWaterhouseCoopers, who will act in
accordance with Article 1592 of the French Civil Code. The fees and expenses of PriceWaterhouseCoopers therefore shall be shared equally between the Grantors on the one hand and the Beneficiary on the other hand. 
  

	7.3	Transfer – Ownership 

  
 Should the Call Option be exercised, the transfer of ownership of the Option Shares (hereinafter referred to as the “Transfer of the Option
Shares”) and the payment of the Option Purchase Price shall occur within 15 days of the later date of (i) the date of the Confirmation of the Call Option and (ii) the final determination of the Option Price as set out in Article 7.2.3 (the
“Transfer of the Option Shares Date”). 
  
 The
Transfer of the Option Shares shall be subject to the submission of: 
  
 - bank checks or irrevocable bank transfers for amounts equal to the price due to each of the Grantors; 
  
 - share transfer forms (ordres de mouvement) or any other relevant instruments instructing the Company to transfer the Option Shares to the
Beneficiary; 
  
 It being certified that the Disclosure Schedule
remitted pursuant to Article 7.1.3 above shall become part of this agreement for the purposes of Articles 7.5 and 8 below. 
  
 The Parties expressly agree that the Beneficiary shall have the use and ownership of the Option Shares as from the Transfer of the Option Shares Date and
that the Option Shares shall be transferred with the right to the dividend attached. 
  
 Notwithstanding Article 7.2.2 here above, in case the Grantors failed to retract and defaulted in any of their obligation under the Call Option and that the Beneficiary gave notice of his offer to pay on time and in
the abovementioned conditions and has escrowed an amount equal to the 
  

 -14- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

 Option Purchase Price on an escrow account at the Caisse des Dépôts et Consignations (the
“Escrow Agent”), the delivery of a copy of the Call Option to the Company together with a copy of the notice to enforce the Call Option and the receipt from the Escrow Agent, will be a sufficient exchange order and the Company will
therefore be required to transcribe the change of ownership of the Option Shares in its book and in the corresponding shareholders’ accounts. The Grantors expressly agree on the foregoing. 
  
 The Company, party to this Agreement, expressly agrees to act as the agent
of the Parties. 
  
 Notwithstanding Article 1142 of the French
Civil code, Parties agree that in case of a default by one Party, the other Party will be authorized to obtain a “specific performance” before a French Court (meaning the transfer of the Option Shares) by exception to damages. 

 

	7.4	Undertakings of the Grantors and the Beneficiary 

  

	 	7.4.1	Undertakings of the Grantors 

  
 For the duration of the Call Option, the Grantors shall not transfer, pledge or grant a security over, or in general otherwise dispose of the Option
Shares in any manner whatsoever. 
  
 For the duration of the Call
Option the Grantors also undertake and will procure (se portent fort) that the Company will limit the shareholding of the Company (without any restriction) to individuals (personnes physiques) who shall accept in writing, before
subsecribing any securities of the Company, to be bound by this Agreement (and shall adhere in writing to this Agreement as “Grantors”) and especially by all the undertakings of the Grantors set out in this Article 7. In addition, none of
those individuals shall be have a controlling interest or be an officer in a company that is a competitor to the Beneficiary. 
  
 For the duration of the Call Option and upon request, the Company and the Grantors undertake to provide the Beneficiary with (i) the monthly
Company’s Sales Revenue for Conceptus Products and the Company’s Sales Revenue for Non-Conceptus Products and (ii) full access to any information and documents (including the financial accounts, the turnover for each of the Sales Revenue
for Conceptus Products and Non-Conceptus product, on a monthly basis and the monthly reporting) in order for the Beneficiary to be able to have a clear understanding of the way the Conceptus Products and Non-Conceptus Products are distinguished and
separated. 
  

	 	7.4.2	Undertakings of the Beneficiary 

  
 In the event the Call Option is exercised and because the Company’s employees have consented a lower remuneration because of the financial situation
of the Companies on the Transfer Date, the Beneficiary undertakes to have the Company’s employees offered the possibility to revert to the employment contracts provisions they benefited from immediately before the Transfer Date as an incentive
to have the Company’s employees remain with the Company. 
  

	7.5	Representations and Warranties of the Managers 

  
 The Managers represent and warrant to the Beneficiary that the statements contained in this Article 7.5 together with the Disclosure Schedule and the Due
Diligence Disclosure will be correct and complete as of the Transfer of the Option Shares Date. 
  

 -15- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	 	7.5.1	Due Diligence 

  
 All the information, agreements and any document whatsoever relating to the Company and its business, including all incurred and potential liabilities
whatsoever, have been disclosed to the Beneficiary in the Due Diligence and are true, complete and accurate. 
  

	 	7.5.2	Incorporation and Existence 

  
 The Companies are duly organized and validly existing. 
  

	 	7.5.3	Shareholding 

  
 An exhaustive list of the Companies Subsidiaries is set forth in the Disclosure Schedule. 
  
 The Companies hold no direct or indirect shareholding in any company existing in law or in fact whatsoever, or in any legal
or other entity other than the Subsidiaries, nor do the Companies serve as a director in law or in fact in any companies or entities whatsoever. The Companies have no outstanding or potential liability with respect to any of its former shareholding.

  

	 	7.5.4	Capitalization 

  
 The Grantors validly own all the Option Shares which represent all of the issued and outstanding share capital of the Company. The Option Shares are free
from and clear of any Lien. There are no options, promises, subscription vouchers or other agreements or undertakings according to which any of the Companies is obliged or may be obliged to create any securities, shares, rights or other transferable
securities. 
  
 Upon consummation of the transactions
contemplated by this Call Option and execution and delivery by the Grantors to the Beneficiary of share transfer forms in respect of the Option Shares in the name of the Beneficiary, the Beneficiary shall have a good title to the Option Shares and
the direct and exclusive control of all dividends and voting rights of the Option Shares. 
  

	 	7.5.5	Accounting and Financial Documents 

  
 The Managers have provided, on the Transfer of the Option Shares Date, the Beneficiary with copies of the audited Company’s consolidated financial
statements if any and the audited annual financial statements of each of the Companies for the last ended fiscal year before the exercise of the Call Option (balance sheet, profit and loss statement and notes on the accounts) (the “Audited
Financial Statements”). 
  
 The Audited Financial
Statements (i) present fairly the financial position of the Companies and the results of operations of the Companies as of the respective dates thereof and for the periods covered thereby; and (ii) were prepared in accordance with the Accounting
Principles, applied on a consistent basis throughout the periods covered thereby. 
  

	 	7.5.6	Contracts 

  
 All agreements entered into by the Companies are listed in the Disclosure Schedule. All such agreements have been entered into in the ordinary course of
business. 
  
 The Transfer of the Option Shares shall not affect
the rights and obligations of the Companies vis-vis third parties and none of the agreements entered into by the Companies 
  

 -16- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

 shall be terminated or cause any indemnification, payment, penalty to be due as a result of the Transfer
of the Option Shares except as disclosed in the Disclosure Schedule but except, for avoidance of doubt, the sub-distributor agreements which are required to not be solely and only affected by a change of control of the Company. 
  

	 	7.5.7	Litigation 

  
 There are no administrative, judicial or arbitration proceedings (including inquiries, claims, complaints, assessments or inspection proceedings of any
nature whatsoever) existing, pending or, to the best knowledge of the Managers, threatened by, against or between the Companies and any other Person, whether the Companies are a plaintiff or a defendant, for itself or on behalf of a Person for which
it may be liable or a guarantor. 
  

	 	7.5.8	Absence of certain changes and events 

  
 Since the last day of the period covered by the Audited Financial Accounts and up to the Transfer of the Option Shares Date the Companies have been
operated in the ordinary course of business consistent with past practice. 
  

	 	7.5.9	Completeness of Representations and Warranties 

  
 The Grantors have not omitted to disclose to the Beneficiary any facts whatsoever that would be necessary in order for the Beneficiary not to be misled by
the information contained herewith including the Disclosure Schedule and the Due Diligence Disclosure or to purchase them for a substantially lower price. The Grantors have made all reasonable efforts to obtain from the Companies the information of
which they represent themselves as being aware of in the representations made herein, including the Disclosure Schedule and Due Diligence Disclosure. 
  
 Each of the warranties and representations herein contained is without prejudice to any other warranty, representation or undertaking and no clause
contained herewith shall restrict or govern the extent or application of any clause. 
  
 There is no fact that Materially Adversely Affects the business, property, condition, results of operations or business prospects of the Companies that has not been notified to the Beneficiary prior to the Transfer of
the Option Shares. 
  
 The representations made herewith, the
warranties granted, and the undertakings agreed to are valid, and shall remain valid, whatever the legal form the Companies may acquire including the Disclosure Schedule and Due Diligence Disclosure. 
  

	8	INDEMNIFICATION 

  

	8.1	Indemnification 

  
 Except as otherwise provided in this Article 8, from and after the Transfer of the Option Shares, the Managers hereby agree to indemnify, defend and hold
harmless the Beneficiary or, at the Beneficiary’s sole option, the Companies (collectively, the “Indemnified Parties”) against and in respect of 100% of any reduction or shortfall in assets, or any increase or surplus in
liabilities whatsoever, and of any prejudice, damage, loss, shortfall in earnings or costs that are suffered directly or indirectly by the Beneficiary or the Companies (including penalties and legal costs), at the Transfer of the Option Shares Date
or may exist in the future and were not expressly disclosed in this Agreement or the Disclosure Schedule or the Due Diligence Disclosure (“Loss” or “Losses”) resulting from or incident to: 
  

	 	1.	any breach or inaccuracy of any representation or warranty made by the Managers in or pursuant to this Agreement or in any certificate or other document delivered in connection
herewith and any misrepresentation made by the Managers in connection with this Agreement or the transactions contemplated hereby; 

  

 -17- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	 	2.	anything the Managers were aware of or should under normal business conditions have been aware of that was not disclosed in the Due Diligence Disclosure; 

 

	 	3.	any events or circumstances having their origin prior to the Transfer of the Option Shares; 

  

	 	4.	any Taxes reassessment incurred by the Companies based on any facts or events having arisen on or prior to the Transfer of the Option Shares. 

  

	8.2	Limitations and Exclusions 

  
 The Indemnified Parties shall not assert any claim for indemnification against the Managers under this Article 8 until such time that the aggregate of all
indemnifiable claims that the Indemnified Parties may have against the Managers under Article 8 shall exceed 100,000 euro, it being specified that in the event this threshold is exceeded, the payment of the indemnity shall become due from the first
euro. The amount of any claim for indemnification against the Managers under this Article 8 will not exceed the Option Purchase Price paid. 
  
 The Managers indemnification obligations under the terms of Article 8 hereof shall be subject to the following conditions: 
  

	 	a)	no indemnification other than that due with respect to interest or penalties for late payment shall be due by the Seller with respect to any Tax reassessments leading only to a
transfer of income or expenses from one fiscal year to another, and that do not give rise to any additional Tax burden for the Companies in comparison to that which they would bear in the absence of such reassessment as a result of, notably, (i) any
variation in the applicable Tax rate, (ii) any increase in Tax liability, resulting interest charges or penalties for late payment, or (iii), any reassessments of Tax liability concerning the opening balance sheet of the first reassessable fiscal
year (bilan d’ouverture du premier exercise non prescrit) pursuant to the principle that the opening balance sheet cannot be changed (intangibilité du bilan d’ouverture); 

  

	 	b)	notwithstanding the fact that a Loss may result from a breach or inaccuracy of more than one of the representations or warranties of this Agreement, the Managers liability may only
be sought once in respect of any given event or damage. 

  

	8.3	Claims 

  
 All claims sent by an Indemnified Party to the Managers (“Claim”) shall be the subject of a written notification setting forth the reasons why the Managers’ obligation to indemnify is being
called into effect, and the amount of the Loss, if it can be determined (“Claim Notice”). Any such Claim Notice shall be sent to the Managers not later than sixty (60) days after the Indemnified Party has become aware of the claimed
breach allegedly giving rise to indemnification hereunder. 
  
 In
the absence of objection by the Managers to the Indemnified Party within thirty (30) days of receipt by it of a Claim Notice, the Managers shall immediately pay to the Beneficiary an amount equal to the indemnifiable Losses set forth therein.

  

 -18- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	8.4	Release 

  
 The Managers may not be released from its obligation to indemnify by invoking any lack of awareness of the facts in question, or any knowledge that the Beneficiary has or may have of the facts giving rise to the
implementation of the obligation to indemnify (e.g., as a result of any investigations made by the Beneficiary). 
  
 Approval by the shareholders’ meeting of the Companies’ accounts for the current fiscal year or any subsequent fiscal year shall not constitute,
where applicable, a waver by any of the Indemnified Parties of any right to indemnification pursuant to Article 8. 
  

	8.5	Payments 

  
 Upon the final determination of the liability under this Article 8 either by mutual agreement or upon a final court judgement or arbitration award (“jugement definitif”), the Managers shall pay to the
Indemnified Party within ten (10) days after such determination, the amount of the claim for indemnification made hereunder. 
  

	8.6	Survival of Representations, Warranties and Indemnity 

  
 All representations and warranties of the Grantors and the Managers shall survive and continue in full force and effect until the second anniversary of
the Transfer of the Option Shares except for social and tax matters, for which the representations and warranties of the Grantors and the 
  
 Managers shall survive and continue in full force and effect until one month after the expiration of the applicable statutes of limitations. 

 
 The termination of any such representation and warranty, however, shall
not affect any claim for any breach of any representation or warranty if written notice thereof is given to the breaching Party within the period of time referred to in Article 8.3 before such termination date mentioned above. 
  

	9	POST TRANSFER OF THE OPTION SHARES - COVENANTS OF THE PARTIES 

  

	9.1	Transition 

  
 The Parties agree that, following the Transfer of the Option Shares, they shall jointly inform the customers with respect to the transfer of control of the Company. The Parties shall mutually agree on the format,
content, place and date of such notices. 
  
 The Grantors shall
not take any action that is designed or intended to have the effect of discouraging any lessor, licensor, customer, supplier, or other business associate of the Company from maintaining the same business relationships with the Company after the
Transfer of the Option Shares as it maintained with the Company and the Subsidiaries if any prior to the Transfer of the Option Shares. The Grantors will refer to the Beneficiary all customer inquiries received by the Grantors from and after the
Transfer of the Option Shares relating to the business of the Companies. 
  

 -19- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	9.2	Non-Competition Undertaking / Non Solicitation of Employees 

  

	 	9.2.1	For three (3) years following the Transfer of the Option Shares, the Managers undertake and shall cause their respective, representatives and employees to undertake, (whether
on their own account or for the account of any other Person), among other things, not to: 

  

	 	(a)	compete, directly or indirectly, either as principal, officer, director, agent, consultant, contractor, joint-venturer, employee, investor or anything else with the Companies;

  

	 	(b)	contact, solicit or endeavor to solicit, approach or do business with, directly or indirectly, any Person who or which is at the date of the Transfer of the Option Shares and who or
which shall have been at any time during the preceding year a client or customer of or in the habit of dealing or doing business with the Companies, for selling or proposing products or services already proposed by the Companies.

  

	 	9.2.2	For three (3) years following the date of the Transfer of the Option Shares, the Managers undertake and shall cause their respective, representatives and employees to undertake,
(whether on their own account or for the account of any other Person), not to contact, solicit or endeavor to entice away from the Companies or hire any person who was employed by it on the date of the Transfer of the Option Shares or at any time
within a period of one year prior to that date, without the Beneficiary’s consent. 

  

	9.3	Grantors’ and Managers’ Agent 

  
 For the purposes of this Agreement, the Grantors and the Managers hereby appoint Yves Guillemain d’Echon as their representative (the
“Grantors’ and Managers’ Agent”), who, in their name and on their behalf, shall make all notices and communications, receive all notices or make all declarations and make all payments which are to be made pursuant to this
Agreement or as a consequence thereof or arising there from, to, or on behalf of, the Grantors and/or the Managers. In view of the mutual interest it represents for the Parties, such power of attorney is irrevocable. Any notification to the
Grantors’ and Mangers’ Agent shall thus be deemed to have been made to each of the Grantors and Managers. 
  
 Should Yves Guillemain d’Echon, hereby appointed, be unable to perform his duties to act as the Grantors’ and Mangers’ Agent, for any
reason whatsoever, Jean-Christophe Bodin will replace Yves Guillemain d’Echon as Grantors’ and Mangers’ Agent. In such case, Jean-Christophe Bodin must notify to each Grantor and Manager and to the Purchaser that he is henceforth
acting as the Grantors’ and Mangers’ ‘ Agent. Should Jean-Christophe Bodin, hereby appointed, be unable to perform his duties to act as the Grantors’ and Mangers’ Agent, for any reason whatsoever, the Grantors’ and
Mangers’ Agent will be appointed among the Grantors by the President of the Commercial Court of Paris ruling in summary form (“en référé”), such ruling not being challengeable in appeal. 
  

 -20- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	9.4	Confidentiality 

  

	 	9.4.1	The Grantors covenant and agree that they shall not disclose to any Person, orally or in writing, formally or informally, any information concerning the businesses and affairs of
the Companies that is not already generally available to the public. 

  

	 	9.4.2	The restrictions imposed by this Article 9.4.2 shall apply as from the Transfer of the Option Shares Date and until its third anniversary. 

  

	10	NOTICES 

  

	10.1	Any notice, request, demand or other communication given with reference to this Agreement (a “Notice”) shall be delivered in English and (i) by hand (with written
confirmation of receipt) to the persons listed hereinafter or (ii) by certified or registered mail, postage prepaid, acknowledgement of receipt requested or (iii) by overnight delivery service or (iii) by facsimile transmission with confirmation of
receipt simultaneously addressed by certified mail. 

  

	10.2	A Notice shall be deemed to have been received (i) if delivered by hand, on the day of such delivery or (ii) if delivered by certified or registered mail or overnight delivery
service, on the day of such delivery or, should the addressee refuse the delivery or be absent on that date, on the day of first presentation of the Notice or (iii) if delivered by fax, on the day on which such fax was sent, provided that a copy is
also sent by registered or certified mail sent no later than the first Business Day following the day the facsimile was sent. 

  

	10.3	Notices shall be sent to the following addresses: 

  

	 	(a)	If to the Seller/Beneficiary, to: 

  
 Mr. Stan Van Gent 
 Conceptus Inc.

 1021 Howard Ave, San Carlos 
 CA, 94019, United States of America 
  
 Fax: +1 650 802
2880 
  
 with a copy to: 
  
 Mr. Mark Siezckarek  
 Conceptus Inc. 
 1021 Howard Ave, San Carlos

 CA, 94019, United States of America 
  
 Fax: +1 650 628 4748 
  

	 	(b)	If to the Purchasers/Grantors, to: 

  
 Mr. Yves Guillemain d’Echon 
 4,
Passage Saladin 
 78000 Versailles 
  
 Fax: +33 1 30 21 19 25 
  

 -21- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	 	(c)	If to the Managers, to: 

  
 Mr. Yves Guillemain d’Echon 
 4,
Passage Saladin 
 78000 Versailles 
  
 Fax: +33 1 30 21 19 25 
  
 or to such other addresses as a Party may notify to the other Party in accordance with this Article 10, it being specified that any notification of a
change of address shall become effective ten (10) days after notification of such change to the other Party. 
  

	11	MISCELLANEOUS 

  

	11.1	Taxes 

  
 The transfer Taxes resulting from the transfer of the Shares to the Purchasers and from the transfer of the Option Shares to the Beneficiary shall be borne respectively by the Purchasers and by the Beneficiary. The
Purchasers and the Beneficiary shall take all necessary steps to fulfill any and all formalities relating thereto. 
  

	11.2	Other Costs and Expenses 

  
 Each Party shall bear its own costs and expenses, including fees of legal and other counsels, incurred in connection with the preparation, execution and
implementation of this Agreement and the transactions contemplated hereby. 
  

	11.3	Calculation of the Periods of Time 

  
 For the calculation of a period of time, such period shall start the next following day after the day on which the event triggering such period of time
has occurred. The expiry date shall be included in the period of time. If the expiry date is not a Business Day, the expiry date shall be postponed until the next Business Day. 
  

	11.4	Amendment 

  
 No terms of this Agreement may be altered, modified, amended, supplemented or terminated except by an instrument in writing duly signed by the Parties. 
  

	11.5	Assignment 

  
 None of the Parties may assign the benefit of any provision of this Agreement without the prior written consent of the other Party, to any Person, including to any subsequent purchaser of all or parts of the Shares or
Option Shares or to a company that shall merge with the Party or to which the Party shall contribute all or substantially all of its assets or its business. 
  

	11.6	Severability 

  
 If any provision herein, or the application thereof to any circumstance of this Agreement, is held to be unenforceable, invalid or illegal by any court,
arbitration tribunal, government agency or regulatory body of competent jurisdiction, (i) such provision shall be deemed deleted from this Agreement or not applicable to such circumstance, as the case may be, and the enforceability, validity and
legality of the other provisions of this Agreement shall not be affected or impaired thereby and (ii) the Parties shall negotiate in good faith to agree on replacement terms that shall be enforceable, valid, legal, and consistent with the initial
intent of the Parties. 
  

 -22- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

	11.7	Single Agreement 

  
 This Agreement (including the Schedules and the Disclosure Schedule) supersedes all prior agreements, negotiations, drafts and understandings among the
Parties hereto. 
  

	11.8	Governing Law - Disputes 

  
 This Agreement shall be exclusively governed by and construed in accordance with French law. All disputes arising out of or in connection with this
Agreement (including without limitation with respect to its signature, validity, performance, interpretation, termination and post-termination obligations hereof) shall be submitted to the exclusive jurisdiction of the Commercial Court of Paris.

  
 Made on the date specified above in twenty (20) originals. 
  

					
	
 Mr. Yves GUILLEMAIN D’ECHON
  
 Pursuant to Article 1415 of the French Civil Code, the undersigned Mrs Catherine Guillemain d’Echon hereby expressly accepts all the
undertakings made by Mr. Yves Guillemain d’Echon pursuant to this Agreement.
	 	 	 	
 CONCEPTUS Inc.
 By:
Mr. Mark SIEZCKAREK
 Title: President and Chief Executive Officer

			
	
 Mrs Catherine GUILLEMAIN D’ECHON
	 	 	 	 
			
	
 Mr. Jean-Christophe BODIN
	 	 	 	
 CONCEPTUS SAS
 By:
Mr. Yves GUILLEMAIN D’ECHON
 Title: President

			
	
 Mrs Catherine GUILLEMAIN D’ECHON
	 	 	 	
 Mr. Florent GUILLEMAIN D’ECHON

			
	
 Mr. Alban GUILLEMAIN D’ECHON
	 	 	 	
 Mr. Tristan GUILLEMAIN D’ECHON

			
	
 Mr. Jean GUILLEMAIN D’ECHON
	 	 	 	
 Mrs. Katia BODIN

  

 -23- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

					
	
 Miss. Fabienne GAIRIN
	 	 	 	
 Miss Isabelle VIROULET

			
	
 Miss Aurélie Blanchard
	 	 	 	
 Mr. Didier PINGET

			
	
 Mr. Eric TOURRAUD
	 	 	 	
 Mr. Philippe MARECHAL

  

 -24- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

 Schedule 2.1 
  

						
	 Purchasers

	  	Number of Shares acquired

	  	Percentage of the share capital

	 
	 Yves Guillemain d’Echon
	  	2994	  	59,87	%
	 Jean-Christophe Bodin
	  	647	  	12,94	%
	 Catherine Guillemain d’Echon
	  	81	  	1,62	%
	 Florent Guillemain d’Echon
	  	81	  	1,62	%
	 Alban Guillemain d’Echon
	  	81	  	1,62	%
	 Tristan Guillemain d’Echon
	  	81	  	1,62	%
	 Jean Guillemain d’Echon
	  	81	  	1,62	%
	 Katia Bodin
	  	364	  	7,28	%
	 Fabienne Gairin
	  	178	  	3,56	%
	 Isabelle Viroulet
	  	121	  	2,43	%
	 Aurélie Blanchard
	  	8	  	0,16	%
	 Didier Pinget
	  	81	  	1,62	%
	 Eric Tourraud
	  	121	  	2,43	%
	 Philippe Maréchal
	  	81	  	1,62	%
	 TOTAL
	  	5.000	  	100	%

  

 -25- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately. 

 Schedule 4.1 
  
 Distribution Agreement 
  

 -26- 
  
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]